Methods of treating overactive bladder using trospium

Locally administering trospium to the bladder addresses the limitations of current overactive bladder treatments by offering sustained symptom relief and improved quality of life through controlled release systems, effectively reducing urinary incontinence and side effects.

JP2024164020APending Publication Date: 2024-11-26TARIS BIOMEDICAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024121447
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-05-20
Filing Date
2024-07-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current treatments for overactive bladder, such as systemic drug therapies and invasive surgical procedures, suffer from low efficacy, dose-limiting side effects, and high costs, while alternative methods like Botox injections require self-catheterization and have adverse event rates.

Method used

Administering trospium locally to the bladder for at least 24 hours provides sustained symptom relief, reducing urinary incontinence episodes and improving quality of life by retraining the bladder through controlled release systems like TAR-302, a trospium-releasing intravesical system.

Benefits of technology

Treats overactive bladder effectively with reduced side effects, providing at least 50% symptom relief for up to 7 days and significantly reducing urinary incontinence episodes over a 6-week period, suitable for patients who have failed oral therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164020000004
    Figure 2024164020000004
  • Figure 2024164020000005
    Figure 2024164020000005
  • Figure 2024164020000006
    Figure 2024164020000006
Patent Text Reader

Abstract

To provide methods of treating overactive bladder and methods of training or retraining bladder, prolonging symptom relief, improving the quality of life and / or neuronal remodeling in an individual having overactive bladder.SOLUTION: The present invention provides a method that includes administering an effective amount of trospium locally to the bladder for at least about 24 hours.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application is a continuation of U.S. Provisional Patent Application No. 62 / 713,414, filed August 1, 2018. and the benefit of U.S. Provisional Patent Application No. 62 / 850,481, filed May 20, 2019. and claims priority thereto. It is incorporated herein by reference in its entirety.

[0002] FIELD OF THEINVENTION This application relates to the treatment of overactive bladder by locally delivering trospium to the bladder, Bladder training or retraining, extended symptom relief, improved quality of life, and / or improved ability to treat overactive bladder The present invention relates to a method of neural remodeling in an individual. [Background technology]

[0003] Lower urinary tract disorders, including overactive bladder, detrusor instability, and urinary incontinence, can result from a number of pathologies. These pathologies are generally classified as neuropathic, myopathic, or idiopathic. The majority are usually characterized as idiopathic, since there is no observable etiology.

[0004] Recent studies have demonstrated that the urothelial sensory system plays an important role in afferent signaling and urinary muscle activity. This suggests that it may be possible to achieve this. andb Exp Pharmacol.2009;(194):91-138;Dal y et al.Current Opinion in Urology 2011, 21:268-274;Birder and Andersson Physiol Rev 93:653-680, 2013. Pathology of this system is specific to the lower urinary tract. It has been suggested that it plays an important role in many patients with onset diseases.

[0005] Standard drug therapy for patients with idiopathic lower urinary tract disorders is typically administered orally or transdermally. These therapies have several limitations, including dose-limiting side effects and limited efficacy. These often lack sufficient efficacy due to either

[0006] Currently, patients who have failed systemic drug therapy have only two alternatives. The first alternative is , direct injection of Botox into the bladder wall, which may provide symptomatic relief, is not desirable. Unfortunately, this can also lead to long-term urinary retention requiring self-catheterization. The proposal is to use neurostimulation, such as that provided by the InterStim® device. The device is surgically implanted and has been shown to provide symptomatic relief. However, the instruments and surgical procedures are expensive, highly invasive, and often require corrective surgery or removal. This results in a 30% adverse event rate.

[0007] Overactive bladder is characterized by urinary incontinence, usually accompanied by urinary frequency and nocturia, with or without urge incontinence. Overactive bladder is a chronic condition characterized by lower urinary tract symptoms of urgency. It is the most common cause of urinary incontinence or loss of bladder control in adults and accounts for approximately 30% of all adults in the United States. The prevalence is similar between men and women in the United States. (16.0% and 16.9%, respectively), the severity and nature of the manifestations differed, with have a higher incidence of urge incontinence, and the prevalence increases significantly with age. Overactive bladder can affect patients whether or not they have symptoms of urge incontinence. This has a significant impact on the health-related quality of life, mental health, and quality of sleep of individuals. The economic burden of overactive bladder is also significant, estimated at approximately $1.2 billion per year. Bladder incontinence is different from stress urinary incontinence, but the situation in which they occur together is usually called mixed urinary incontinence. It is known as.

[0008] The urothelial sensory system is composed of numerous receptors and signaling pathways, many of which are important Due to the complexity of the urinary tract sensory system, selective agents such as darifenacin , may not adequately modulate urothelial sensory activation following nonspecific noxious stimuli. Nonspecific agents such as oxybutynin, which exhibit antimuscarinic and calcium channel activity, , which does not inhibit urothelial response as measured by intercontraction interval, but results in urinary retention obtain. Summary of the Invention [Problem to be solved by the invention]

[0009] Thus, more and better treatment options for lower urinary tract disorders, including overactive bladder There remains a need for novel therapeutic approaches. Desirably, such treatments would involve systemic administration of drugs, as well as This would address one or more of the problems associated with highly invasive and expensive surgical procedures. Desirably, this treatment also eliminates the need for painful injections and repeated self-catheterization. Desirably, the treatment will produce a durable response. There will be.

[0010] Disclosure of all publications, patents, patent applications, and published applications mentioned herein is incorporated herein by reference in its entirety. [Means for solving the problem]

[0011] In some embodiments, the present invention provides a method for administering an effective amount of trospium to a subject for at least about 24 hours. and locally administering to the individual's bladder a method for training the bladder of an individual having an overactive bladder. A method is provided.

[0012] In some embodiments, the present invention provides a method for administering an effective amount of trospium to a subject for at least about 24 hours. Methods for prolonging symptomatic relief in individuals with overactive bladder, comprising administering The method provides an individual with at least about 24 hours of symptom relief after trospium administration is completed. Experience peace.

[0013] In some embodiments, the present invention provides a method for administering an effective amount of trospium to a subject for at least about 24 hours. and a method for improving the quality of life of an individual with an overactive bladder, comprising administering the A method is provided whereby an individual's quality of life is improved with treatment with trospium.

[0014] In some embodiments according to any of the above methods, the individual with overactive bladder is Approximately 50% relief of baseline symptoms for at least approximately 7 days after lospium administration is completed Experience.

[0015] In some embodiments of any of the methods described above, trospium is administered at least about 4 The drug is administered topically to the bladder continuously for two days.

[0016] In some embodiments according to any of the methods described above, the method further comprises administering to the subject an effective amount of trospirus. The method further comprises administering the compound to the bladder about every three months or as needed (prn).

[0017] In some embodiments, the present invention provides a method for administering an effective amount of trospium for at least about 42 days. and a method for treating overactive bladder comprising administering locally and continuously to the bladder of an individual. will be done.

[0018] In some embodiments of any of the above methods, trospium is administered for about 56 days or In some embodiments, trospium is administered continuously for at least about 12 weeks. The treatment will be administered continuously for two weeks.

[0019] In some embodiments, the present invention provides a method for administering trospium to the bladder for at least about 24 hours. Also provided is a method for the maintenance treatment of overactive bladder in an individual, comprising administering continuously and locally In some embodiments, an effective amount of of trospium administered topically to the bladder for at least about 24 hours every three months. In some embodiments, maintenance therapy includes an effective amount of trospium as needed (prn ) locally to the bladder for at least about 24 hours. Upon recurrence of symptoms, an effective amount of trospium is administered locally to the bladder for at least about 24 hours. In some embodiments, the individual has at least 50% improvement in baseline symptoms. When experiencing a relapse, administer an effective amount of trospium topically to the bladder for at least about 24 hours. In some embodiments, the prior treatment comprises administering an effective amount of trospium for at least about 24 hours, at least about 42 days, at least about 56 days, or also includes administering the compound locally to the bladder for about 12 weeks.

[0020] In some embodiments of any of the methods described above, the concentration of trospium in the bladder is In some embodiments, the trospium dose is about 0.1 to 100 μg / mL. The concentration of trospium in the plasma of an individual is less than approximately 2 ng / mL during administration of trospium. be.

[0021] In some embodiments of any of the methods described above, the individual has idiopathic overactive bladder. do.

[0022] In some embodiments of any of the methods described above, the individual is diagnosed with multiple sclerosis, Alzheimer's disease, or Alzheimer's disease. Have Hymer's disease, Parkinson's disease or have previously had a stroke.

[0023] In some embodiments according to any of the methods described above, the individual has previously been treated for overactive bladder. I have failed in the past.

[0024] In some embodiments according to any of the methods described above, the individual has previously been treated for overactive bladder. I have never received this.

[0025] In some embodiments according to any of the methods described above, the individual has failed oral therapy or , ineligible for oral therapy.

[0026] In some embodiments of any of the methods described above, the individual is diagnosed with urinary incontinence or urge incontinence. has.

[0027] In some embodiments according to any of the methods described above, the method further comprises administering to the subject a therapeutically effective amount of In some embodiments, the urgency, frequency, or In some embodiments, symptomatic relief of urinary incontinence is achieved. In some embodiments, the individual's quality of life score is improved. In some embodiments, the individual's voiding burden score is reduced. In an embodiment, the method reduces the abnormal urge to urinate.

[0028] In some embodiments according to any of the methods described above, trospium is administered by intravesical administration. The drug is administered to the bladder by using a catheter. [Brief description of the drawings]

[0029] Reference will now be made to the drawings, which are shown by way of example only and not by way of limitation, in which similar elements In the detailed description, the use of the same reference numbers indicates similar or identical sections. The present disclosure will now be described with reference to the accompanying drawings, which show an embodiment of the present disclosure. The embodiments may include elements, components, and / or configurations other than those shown in the drawings. Some of the illustrated elements, components, and / or structures may not be present in certain embodiments. That's fine. [Figure 1A] FIG. 13 is a cross-sectional side view of one embodiment of a resilient portion of a device including constraining end plugs. [Figure 1B] FIG. 1B is a cross-sectional end view of the embodiment of FIG. 1A. [Figure 1C] FIG. 1B is a cross-sectional side view of the device of FIG. 1A when the reservoir is not under osmotic pressure. [Figure 1D] FIG. 1B is a cross-sectional side view of the device of FIG. 1A when the reservoir is under osmotic pressure. [Diagram 2] FIG. 1 is a cross-sectional side view of one embodiment of a device having a preformed sidewall orifice and two captive end plugs. [Figure 3A] FIG. 1 is a plan view of one embodiment of a device having a preformed sidewall orifice and two captive end plugs. [Figure 3B] FIG. 3B is a cross-sectional enlarged view of one of the end plugs of FIG. 3A. [Figure 3C] FIG. 3C is an exploded perspective view of the end plug of FIG. 3B. [Figure 4] FIG. 1 is a cross-sectional end view of one embodiment of a drug delivery device. [Figure 5A] FIG. 1 is a plan view of one embodiment of a drug delivery device having a constraining plug and a preformed ejection port. [Figure 5B] FIG. 5B is an enlarged cross-sectional view of the device of FIG. 5A. [Figure 6A] FIG. 1 is a plan view of one embodiment of a drug delivery device having a constraining plug and a preformed ejection port. [Figure 6B] FIG. 6B is an enlarged cross-sectional view of the device of FIG. 6A. [Figure 7A] 12A shows a plan view of an intravesical device that may be used to provide localized and continuous delivery of trospium or another therapeutic agent. [Figure 7B] Figure 12B is a cross-sectional view taken along line 3-3 in Figure 12A, showing an intravesical device that may be used to provide localized and continuous delivery of trospium or another therapeutic agent. [Figure 7C] 12A-12C show an intravesical device that can be used to provide localized and continuous delivery of trospium or another therapeutic agent. FIG. 12C is a view of one end of the device disposed within a working channel of a deployment instrument, shown in partial cross-section. [Figure 8] Daily urinary recovery of trospium assessed on days 3, 7, 21, 35, 42, and 56 after insertion of TAR-302 is shown. [Figure 9A] A scheme of the study (Figure 9A) is shown. [Figure 9B] The mean daily incontinence episodes (Figure 9B) assessed at days 0 (baseline), 42, and 84 after insertion of TAR-302 are shown. [Figure 10A] Figure 10 shows the efficacy of overactive bladder treatment. Figure 10A shows the change in daily urge incontinence episodes in patients with oral refractory overactive bladder at the end of dosing after TAR-302 or Botox treatment. [Figure 10B]Figure 10B shows the effectiveness of overactive bladder treatment. Figure 10B shows the reduction in daily urge incontinence episodes in oral intolerant overactive bladder patients after VEScare (Solifenacin succinate) or Detrol (Tolterodine tartrate) treatment, compared with the reduction in daily urge incontinence episodes in oral refractory patients after TAR-302 treatment. [Figure 11] Shown are voiding burden scores for individuals treated with TAR-302 calculated prior to treatment with TAR-302, on day 42 at the end of dosing with TAR-302, and on day 84, 42 days after TAR-302 had been cleared. [Figure 12] Shown are quality of life scores for individuals treated with TAR-302 calculated before treatment with TAR-302, on day 42 at the end of dosing with TAR-302, and on day 84, 42 days after TAR-302 had been removed. [Figure 13] 1 shows an exemplary questionnaire for assessing distress scores. [Figure 14] 1 shows an exemplary questionnaire for assessing quality of life scores. [Figure 15A] A scheme of the study (Figure 15A) is shown. [Figure 15B] The mean daily incontinent episodes (FIG. 15B) assessed on days 0 (baseline), 14, 56, and 84 after insertion of TAR-302 are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The present application provides a method for administering an effective amount of trospium locally (e.g., intravesically) to an individual with overactive bladder. Administration of these drugs (e.g., into the bladder) may provide long-term symptomatic relief (e.g., reduced urinary incontinence). Based at least in part on Applicant's striking discovery that Phase I clinical trials , a passive, non-reabsorbable drug whose primary mode of action is the controlled release of trospium into the bladder for approximately 42 days. TAR-302, a rapid trospium-releasing intravesical system, delivers trospium to the bladder. Not only did the number of urinary incontinence episodes decrease during the 42 days of treatment, but The method of the present invention also demonstrated a surprisingly significant reduction in urinary incontinence episodes over the first 6 weeks of treatment. , and side effects are reduced with higher concentrations of trospium locally in the bladder. This has substantial advantages over previous methods of bladder treatment, including oral therapy with urinary bladder stimulants. Thus, in some aspects, the present invention provides a method for treating idiopathic overactive bladder in patients who have failed oral therapy. It is particularly suitable for individuals who may have severe resealant disease. In an aspect, the present application provides a method of training or retraining the bladder in an individual with an overactive bladder. In some aspects, the present application relates to a method for prolonging symptomatic relief in an individual with overactive bladder. In some aspects, the present application provides a method for treating bladder dysfunction in an individual with overactive bladder. In some aspects, the present application provides a method for treating an individual with overactive bladder. The present invention provides a method for improving the quality of life in

[0031] definition As used herein, unless the context clearly indicates otherwise, the singular forms "a," "an," and " "The" includes plural referents. For example, "a" or "an" means "at least either "one" or "one or more."

[0032] As used herein, the term "individual" refers to a mammal, such as a human. Examples of such animals include, but are not limited to, rats, bovine, equine, feline, canine, rodent, or primate. In some embodiments, the individual is a human.

[0033] As used herein, the term "effective amount" refers to an amount of a compound that is effective to treat a particular disorder, condition, or disease. , e.g., ameliorating, alleviating, reducing, and / or delaying one or more of the symptoms thereof. "Amount of a compound or composition sufficient to cause, for example,

[0034] Reference herein to "about" a value or parameter relates to the value or parameter itself. For example, "about 7 days" includes 7 days.

[0035] As used herein, the term "about X to Y" has the same meaning as "about X to about Y". In addition, as used herein, "about X to Y" has the same meaning as "about X to about Y." do.

[0036] As used herein, "treatment" or "treating" refers to any beneficial or ineffective outcome, including clinical results. A beneficial or desired clinical outcome for the purposes of the present invention is an approach to achieve a desired outcome. A therapeutic outcome may include, but is not limited to, alleviating one or more symptoms resulting from a disease. and reducing the severity of the disease, stabilizing the disease (e.g., preventing or slowing the progression of the disease). preventing or delaying recurrence of the disease; retarding or slowing the progression of the disease. to induce a state of disease; or to induce remission of a disease state; or to administer one or more other drugs necessary to treat the disease. Reducing the dosage of medications, slowing disease progression, and / or improving quality of life The method of the present invention includes one or more of the following: The present invention contemplates any one or more of the following:

[0037] method In one aspect, the present application provides a method for administering an effective amount of trospium to the bladder of an individual for at least about 24 hours.

[0023] To train (or retrain) the bladder of an individual with an overactive bladder, including administering In some embodiments, trospium is administered for at least about 3, 5, or 6 hours. In some embodiments, trospium is administered for at least about 2, 3, 4, or 5 days. Administer for 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks. In some embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, mg / day to 20 mg / day, about 2 mg / day to 10 mg / day, about 4 mg / day to 8 mg / day In some embodiments, the urinary trospium concentration is Medium, about 0.1μg / mL to about 20μg / mL, about 1μg / mL to about 10μg / mL, about 2 μg / mL~about 8μg / mL, about 3μg / mL~about 7μg / mL, or about 3μg / mL~ In some embodiments, trospium is administered continuously or intermittently. In some embodiments, an individual with overactive bladder is administered trospium. After completion of the study, the patient should be at baseline for at least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks. In some embodiments, the individual experiences at least about 50% alleviation of symptoms of hyperactivity. The patient is undergoing prior treatment for arterial bladder disease. In some embodiments, the prior treatment is oral therapy. In some embodiments, the individual is non-responsive or refractory to a prior treatment. In some embodiments, the individual is a human. In some embodiments, the individual is In some embodiments, the individual has multiple sclerosis, Alzheimer's disease, or idiopathic overactive bladder. If you have Heimer's disease, Parkinson's disease or have previously had a stroke.

[0038] The present application also provides for the administration of an effective amount of trospium for at least about 42 days (e.g., about 42, 56 , 70, or 84 days) to the bladder of an individual having overactive bladder. Methods for training (or retraining) the bladder of an individual are provided. In some embodiments, trospium is administered for at least about 56 days. In some embodiments, the method is performed using an intravesical delivery device. In some embodiments, trospium is administered by Approximately 1mg / day to 100mg / day, approximately 1mg / day to 20mg / day, approximately 2mg / day to 10mg In some embodiments, the urinary Trospium concentrations range from about 0.1 μg / mL to about 20 μg / mL while trospium is being administered. g / mL, approximately 1μg / mL to approximately 10μg / mL, approximately 2μg / mL to approximately 8μg / mL, approximately 3 1 μg / mL to about 7 μg / mL, or about 3 μg / mL to about 5 μg / mL. In embodiments, trospium is administered continuously or intermittently. , individuals with overactive bladder should be treated with trospium for at least about 7 days, 2 weeks, or more after trospium administration is completed. , at least about 50% relief of baseline symptoms for 3, 4, 5, or 6 weeks In some embodiments, the individual has had prior treatment for overactive bladder. In some embodiments, the prior treatment is an oral therapy. Unresponsive or refractory to prior treatment. The individual is a human. In some embodiments, the individual has idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, Alzheimer's disease, Parkinson's disease. have had a stroke or have previously had a stroke.

[0039] The present application also provides for the administration of an effective amount of trospium for at least about 42 days (e.g., about 42, 56 , 70, or 84 days) to the bladder of an individual having overactive bladder. The present invention provides a method for training (or retraining) the bladder of an individual, the individual having undergone a prior treatment. and the individual is refractory to the prior treatment. In some embodiments, trospium is administered for at least about 56 days. ) is administered for at least about 84 days. In some embodiments, trospium is administered at least In some embodiments, the prior treatment is an oral therapy. In some embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, / day to 20mg / day, about 2mg / day to 10mg / day, about 4mg / day to about 8mg / day In some embodiments, the concentration of trospium in urine is During this period, the concentration ranged from about 0.1 μg / mL to about 20 μg / mL, and from about 1 μg / mL to about 10 μg / mL. mL, about 2 μg / mL to about 8 μg / mL, about 3 μg / mL to about 7 μg / mL, or about 3 μ In some embodiments, trospium is administered continuously or In some embodiments, the individual with overactive bladder is administered trospiu At least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after completion of administration of In some embodiments, the individual experiences at least about 50% relief of baseline symptoms. The body is a human. In some embodiments, the individual has idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, Alzheimer's disease, Parkinson's disease. have had a stroke or have previously had a stroke.

[0040] In another aspect, the present application provides a method for administering an effective amount of trospium topically to the bladder for at least about 24 hours. and (c) administering to an individual a therapeutically effective amount of a bladder inhibitor, The individual experiences symptom relief for at least about 24 hours after trospium administration is completed. In some embodiments, the long-term symptoms of urgency, frequency, urinary incontinence and / or urge incontinence. Relief is achieved. In some embodiments, the individual feels relief shortly after trospium administration is completed. In some embodiments, the patient experiences symptom relief for at least about 1, 2, 3, 4, 5, or 6 weeks. In some embodiments, trospium is administered for at least about 3, 5, or 7 days. So, trospium should be administered for at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 In some embodiments, the intravesical delivery device is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks. In some embodiments, trospium is administered by using a Spium: about 1mg / day to 100mg / day, about 1mg / day to 20mg / day, about 2mg / day In some embodiments, the dosage is from about 4 mg / day to about 8 mg / day. The urinary concentration of trospium was approximately 0.1 μg / mL while trospium was being administered. ~about 20μg / mL, about 1μg / mL to about 10μg / mL, about 2μg / mL to about 8μg / mL, about 3 μg / mL to about 7 μg / mL, or about 3 μg / mL to about 5 μg / mL. In some embodiments, trospium is administered continuously or intermittently. In embodiments, the individual with overactive bladder receives a bladder respiration rate of at least about 7 days after trospium administration is completed. At least about 5 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after baseline symptoms In some embodiments, the individual has undergone prior treatment for overactive bladder. In some embodiments, the prior treatment is an oral therapy. In some cases, the individual is unresponsive or refractory to prior treatment. In embodiments, the individual is a human. In some embodiments, the individual is a human suffering from idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, Alzheimer's disease, Parkinson's disease, or Have Son's disease or have previously had a stroke.

[0041] The present application also provides a method for administering an effective amount of trospium topically to the bladder for at least about 42 days (e.g., For example, a method for treating overactive bladder comprising administering the The present invention provides a method for extending symptomatic relief in an individual receiving trospium therapy, the individual receiving trospium therapy being administered for a short period after trospium administration is completed. In some embodiments, the patient experiences relief from symptoms for at least about 24 hours. Long-term symptomatic relief of frequency, urinary incontinence and / or urge incontinence is achieved. In some embodiments, the individual receives at least about 1, 2, 3, 4, 5, or 6 days after completion of trospium administration. In some embodiments, the patient experiences symptom relief for at least six weeks. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, trospium is administered for at least about 100 days. In some embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, mg / day to 20 mg / day, about 2 mg / day to 10 mg / day, about 4 mg / day to about 8 mg / day In some embodiments, the concentration of trospium in urine is During administration, about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL to about 10 μg / mL g / mL, about 2 μg / mL to about 8 μg / mL, about 3 μg / mL to about 7 μg / mL, or about In some embodiments, trospium is administered continuously. In some embodiments, the individual with overactive bladder is administered thoracic acid or bladder excretion. At least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after completion of pium administration In some embodiments, the patient experiences at least about 50% relief of baseline symptoms during the treatment. In some embodiments, the individual has had a prior treatment for overactive bladder. In some embodiments, the individual is unresponsive to or has not responded to a prior treatment. In some embodiments, the individual is a human. In some embodiments, the individual has idiopathic overactive bladder. have sclerosis, Alzheimer's disease, Parkinson's disease, or have previously suffered a stroke I have been there.

[0042] The present application also provides for the administration of an effective amount of trospium for at least about 42 days (e.g., about 42, 56 , 70, or 84 days) of administering the compound to the bladder of an individual with overactive bladder. The present invention provides a method for extending symptomatic relief, the method comprising administering to an individual at least about 10 minutes after trospium administration is completed. 24 hours (e.g., at least about 2, 5, 7, 10, 15, 2 0, 25, 30, 35, and 40 days) experienced symptom relief and the individual had received prior treatment. and the individual is refractory to prior treatment. Long-term symptomatic relief of frequency, urinary incontinence and / or urge incontinence is achieved. In some embodiments, the individual receives at least about 1, 2, 3, 4, 5, or 6 days of trospium administration after the administration is completed. In some embodiments, the patient experiences symptom relief for at least six weeks. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, trospium is administered for at least about 100 days. In some embodiments, the preceding treatment is an oral therapy. In some embodiments, the trospium is administered by using a delivery device. , trospium about 1mg / day to 100mg / day, about 1mg / day to 20mg / day, about 2m g / day to 10 mg / day, with doses of about 4 mg / day to about 8 mg / day. In this form, the concentration of trospium in urine is approximately 0.1 μg while trospium is being administered. / mL ~ approx. 20 μg / mL, approx. 1 μg / mL ~ approx. 10 μg / mL, approx. 2 μg / mL ~ approx. 8 μg / mL, about 3 μg / mL to about 7 μg / mL, or about 3 μg / mL to about 5 μg / mL In some embodiments, trospium is administered continuously or intermittently. In some embodiments, the individual with overactive bladder receives at least one dose of trospium after administration is completed. At least 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after the onset of baseline symptoms. In some embodiments, the individual is a human. In embodiments, the individual has idiopathic overactive bladder. In some embodiments, the individual is Have multiple sclerosis, Alzheimer's disease, Parkinson's disease, or have had a previous stroke I've had that happen to me before.

[0043] In another aspect, the present application provides a method for administering an effective amount of trospium topically to the bladder for at least about 24 hours. The present invention provides a method for neural remodeling in an individual with overactive bladder, comprising administering Neuronal remodeling was observed for at least about 24 hours after trospium administration was completed ( At least about 2, 5, 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, In some embodiments, the trospium is administered for at least about 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 3 In some embodiments, trospium is administered for at least about 2, 3, 4, 5, 6, 7, or 8 days. Administer for 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks In some embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, Approximately 1mg / day to 20mg / day, approximately 2mg / day to 10mg / day, approximately 4mg / day to approximately 8mg / day In some embodiments, the urinary concentration of trospium is During administration of the drug, the concentration is about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL to about 1 0μg / mL, about 2μg / mL to about 8μg / mL, about 3μg / mL to about 7μg / mL, or In some embodiments, trospium is administered concomitantly at a dose of about 3 μg / mL to about 5 μg / mL. In some embodiments, the individual with overactive bladder is administered At least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or In some embodiments, the patient experiences at least about 50% relief from baseline symptoms for 6 weeks. In some embodiments, the individual has had a prior treatment for overactive bladder. In some embodiments, the individual is unresponsive to or has been treated with a prior therapy. In some embodiments, the individual is a human. In embodiments, the individual has idiopathic overactive bladder. have progressive sclerosis, Alzheimer's disease, Parkinson's disease, or have had a previous stroke I have done that before.

[0044] In another embodiment, the present application provides a method for administering an effective amount of trospium to a subject for at least about 42 days (e.g., for about 42, 56, 70, or 84 days) to treat patients with overactive bladder, including administering The present invention provides a method for neuronal remodeling in an individual, the neuronal remodeling being achieved by administering trospium At least about 24 hours after completion of trospium administration (approximately 2, 5, 7, 10 , 15, 20, 25, 30, 35, 40 days, etc. Trospium is administered for at least about 56 days. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, the administration is by use of an intravesical delivery device. Thus, trospium is administered. In some embodiments, trospium is administered at about 1 mg / mL. ~100mg / day, about 1mg / day ~ 20mg / day, about 2mg / day ~ 10mg / day, about 4 In some embodiments, urinary trospium is administered at a dose of about 8 mg / day to about 10 mg / day. The concentration of trospium is about 0.1 μg / mL to about 20 μg / mL while it is being administered. Approximately 1μg / mL to approximately 10μg / mL, approximately 2μg / mL to approximately 8μg / mL, approximately 3μg / mL In some embodiments, the concentration is from about 3 μg / mL to about 5 μg / mL. In some embodiments, the patient is administered trospium continuously or intermittently. The individual with the bladder is then treated with trospium for at least about 7 days, 2 weeks, 3 weeks, or 4 weeks after completion of the trospium treatment. Experience at least about 50% relief of baseline symptoms for 4, 5, or 6 weeks In some embodiments, the individual has had prior treatment for overactive bladder. In some embodiments, the prior treatment is an oral therapy. In some embodiments, the individual is a human In some embodiments, the individual has idiopathic overactive bladder. In the morphology, the individual may have multiple sclerosis, Alzheimer's disease, Parkinson's disease, Or have previously had a stroke.

[0045] In another embodiment, the present application provides a method for administering an effective amount of trospium to a subject for at least about 42 days (e.g., for about 42, 56, 70, or 84 days) to treat patients with overactive bladder, including administering The present invention provides a method for neuronal remodeling in an individual, the neuronal remodeling being achieved by administering trospium At least about 24 hours after administration is completed (e.g., at least about 24 hours after administration of trospium is completed) 2, 5, 7, 10, 15, 20, 25, 30, 35, 40 days) and the individual was pretreated In some embodiments, the individual is currently undergoing treatment with a prior therapy and the individual is refractory to the prior treatment. Trospium is administered for at least about 56 days. In some embodiments, trospium is administered for at least about 56 days. The administration is for about 100 days. In some embodiments, the prior treatment is an oral therapy. In an embodiment, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, Doses of about 2 mg / day to 20 mg / day, about 2 mg / day to 10 mg / day, and about 4 mg / day to about 8 mg / day In some embodiments, the concentration of trospium in the urine is During this period, the concentration is about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL to about 10 μg / mL L, about 2 μg / mL to about 8 μg / mL, about 3 μg / mL to about 7 μg / mL, or about 3 μg In some embodiments, trospium is administered continuously or In some embodiments, the individual with overactive bladder is administered trospium After administration is completed, the patient should be kept on the vein for at least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks. In some embodiments, the individual experiences at least about 50% relief of baseline symptoms. In some embodiments, the individual has idiopathic overactive bladder. In this embodiment, the individual has multiple sclerosis, Alzheimer's disease, Parkinson's disease. or have previously had a stroke.

[0046] In another aspect, the present application provides a method for administering an effective amount of trospium topically to the bladder for at least about 24 hours. The present invention provides a method for improving quality of life in individuals with overactive bladder, comprising administering As a result, the individual's quality of life improves approximately 24 hours after trospium administration is completed. In some embodiments, the individual has an improved quality of life score. In some embodiments, the individual has a reduced voiding burden score. In some embodiments, trospium is administered for at least about 56 days. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, the administration is by use of an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day. ~100mg / day, approximately 1mg / day ~20mg / day, approximately 2mg / day ~10mg / day, approximately 4m In some embodiments, the urinary trospium concentration is about 100 mg / day to about 50 mg / day. The concentration ranges from about 0.1 μg / mL to about 20 μg / mL, and about 1μg / mL ~ approx. 10μg / mL, approx. 2μg / mL ~ approx. 8μg / mL, approx. 3μg / mL ~ In some embodiments, the concentration is about 7 μg / mL, or about 3 μg / mL to about 5 μg / mL. In some embodiments, trospium is administered continuously or intermittently. Individuals with trospium should be treated with at least about 7 days, 2 weeks, 3 weeks, 4 weeks, or The patient experiences at least about 50% relief of baseline symptoms for a period of one, two, three, or four weeks. In some embodiments, the individual has had prior treatment for overactive bladder. In some embodiments, the prior treatment is an oral therapy. In some embodiments, the individual is a human. In some embodiments, the individual has idiopathic overactive bladder. In certain conditions, the individual may have multiple sclerosis, Alzheimer's disease, Parkinson's disease, or In some embodiments, the individual is administered an intravesical device. It has the following features:

[0047] In another embodiment, the present application provides a method for administering an effective amount of trospium to a subject for at least about 42 days (e.g., for about 42, 56, 70, or 84 days) to treat patients with overactive bladder, including administering The present invention provides a method for improving quality of life in an individual who is receiving trospium therapy, the quality of life being measured after the completion of trospium therapy. at least about 24 hours after completion of trospium administration (at least about 2, 5, 7, 10, 15, 2 In some embodiments, the individual is improved for 0, 25, 30, 35, 40 days, etc. In some embodiments, the individual has an improved quality of life score. In some embodiments, trospium is administered for at least about 56 days. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, trospium is administered for at least about 100 days. In embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to 100 mg / day, about 1 mg / day to Administered at a dose of 20 mg / day, approximately 2 mg / day to 10 mg / day, or approximately 4 mg / day to approximately 8 mg / day In some embodiments, the concentration of trospium in the urine is During this period, about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL to about 10 μg / mL, About 2 μg / mL to about 8 μg / mL, about 3 μg / mL to about 7 μg / mL, or about 3 μg / mL In some embodiments, trospium is administered continuously or intermittently. In some embodiments, the individual with overactive bladder is administered trospium. At least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after the completion of the In some embodiments, the individual experiences at least about a 50% alleviation of line symptoms. The patient is undergoing prior treatment for overactive bladder. In some embodiments, the prior treatment is an oral therapy. In some embodiments, the individual is a patient who has not responded to or has been refractory to a prior treatment. In some embodiments, the individual is a human. The body has idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, amyloidosis, bladder syndrome, idiopathic overactive bladder, idiopathic urinary tract infection ... have Alzheimer's disease, Parkinson's disease, or have previously had a stroke In some embodiments, the individual has an intravesical device.

[0048] In another embodiment, the present application provides a method for administering an effective amount of trospium to a subject for at least about 42 days (e.g., for about 42, 56, 70, or 84 days) to treat patients with overactive bladder, including administering The present invention provides a method for improving quality of life in an individual who is receiving trospium therapy, the quality of life being measured after the completion of trospium therapy. The improvement occurs at least about 24 hours after the individual has been diagnosed with refractory to the prior treatment. In some embodiments, the individual has an improved quality of life score. In some embodiments, the individual has a reduced voiding burden score. In some embodiments, trospium is administered for at least about 56 days. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, the administration is by use of an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day. ~100mg / day, approximately 1mg / day ~20mg / day, approximately 2mg / day ~10mg / day, approximately 4m In some embodiments, the urinary trospium concentration is about 100 mg / day to about 50 mg / day. The concentration ranges from about 0.1 μg / mL to about 20 μg / mL, and about 1μg / mL ~ approx. 10μg / mL, approx. 2μg / mL ~ approx. 8μg / mL, approx. 3μg / mL ~ In some embodiments, the concentration is about 7 μg / mL, or about 3 μg / mL to about 5 μg / mL. In some embodiments, trospium is administered continuously or intermittently. Individuals with trospium should be treated with at least about 7 days, 2 weeks, 3 weeks, 4 weeks, or The patient experiences at least about 50% relief of baseline symptoms for a period of one, two, three, or four weeks. In some embodiments, the individual has had prior treatment for overactive bladder. In some embodiments, the prior treatment is an oral therapy. In some embodiments, the individual is a human. In some embodiments, the individual has idiopathic overactive bladder. In certain conditions, the individual may have multiple sclerosis, Alzheimer's disease, Parkinson's disease, or In some embodiments, the individual is administered an intravesical device. It has the following features:

[0049] Also provided herein is the administration of an effective amount of trospium for at least about 42 days (e.g., for at least about 42 days). , 56, 70, or 84 days) of life in the individual, including administering the Methods to improve quality of life scores are also provided, and quality of life is improved slightly after trospium treatment is completed. In some embodiments, the improvement in quality of life is improved after about 24 hours. In some embodiments, the improvement in quality of life is measured as a quality of life score obtained by measuring the improvement in quality of life. In some embodiments, trospium is administered at a low In some embodiments, trospium is administered for at least about 8 days. In some embodiments, trospium is administered for at least about 100 days. In some embodiments, the intravesical delivery device is used to deliver trospiral In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day. day, about 1mg / day to 20mg / day, about 2mg / day to 10mg / day, about 4mg / day to about 8mg g / day. In some embodiments, the urinary concentration of trospium is While thiamine is being administered, the concentration is about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL to Approximately 10μg / mL, approximately 2μg / mL to approximately 8μg / mL, approximately 3μg / mL to approximately 7μg / mL In some embodiments, trospium In some embodiments, the individual with overactive bladder is administered , at least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks after trospium administration is completed, or experience at least about 50% relief of baseline symptoms for 6 weeks. In some embodiments, the individual has had a prior treatment for overactive bladder. The treatment is an oral therapy. In some embodiments, the individual is unresponsive or has a history of a prior treatment. The patient is refractory to prior therapy. In some embodiments, the individual is a human. In some embodiments, the individual has idiopathic overactive bladder. , multiple sclerosis, Alzheimer's disease, Parkinson's disease, or a previous stroke In some embodiments, the individual has an intravesical device. .

[0050] As used herein, an effective amount of trospium is administered for at least about 42 days (e.g., about 42, 56 , 70, 84 days) to administer topically to the bladder, and a method for reducing the quality of life of at least about 10 days after completion of trospium administration is provided. In some embodiments, the improvement in quality of life is improved after 24 hours. In some embodiments, the improvement in quality of life is measured as a quality of life score of In some embodiments, trospium is administered at least once a day. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, trospium is administered for at least about 100 days. In some embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, 1mg / day to 20mg / day, about 2mg / day to 10mg / day, about 4mg / day to about 8mg / day In some embodiments, the urinary concentration of trospium is During administration, about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL to about 10 μg / mL, about 2 μg / mL to about 8 μg / mL, about 3 μg / mL to about 7 μg / mL, or In some embodiments, the amount of trospium is about 3 μg / mL to about 5 μg / mL. In some embodiments, trospium is administered continuously or intermittently for at least about 84 days. In some embodiments, the individual with overactive bladder is administered trospium. At least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after the completion of the In some embodiments, the individual experiences at least about a 50% alleviation of line symptoms. The patient is undergoing prior treatment for overactive bladder. In some embodiments, the prior treatment is an oral therapy. In some embodiments, the individual is a patient who has not responded to or has been refractory to a prior treatment. In some embodiments, the individual is a human. The body has idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, amyloidosis, bladder syndrome, idiopathic overactive bladder, idiopathic urinary tract infection ... have Alzheimer's disease, Parkinson's disease, or have previously had a stroke In some embodiments, the individual has an intravesical device.

[0051] In another embodiment, the present application provides a method for administering an effective amount of trospium to a subject for at least about 42 days (e.g., for about Continuously administering the compound to the bladder of an individual for 42, 56, 70, or 84 days; Methods for treating overactive bladder are provided. In some embodiments, the method comprises administering less trospium. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, trospium is administered for at least about 100 days. In some embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, Approximately 1mg / day to 20mg / day, approximately 2mg / day to 10mg / day, approximately 4mg / day to approximately 8mg / day In some embodiments, the urinary concentration of trospium is During administration of the drug, the concentration is about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL to about 1 0μg / mL, about 2μg / mL to about 8μg / mL, about 3μg / mL to about 7μg / mL, or In some embodiments, trospium is administered concomitantly at a dose of about 3 μg / mL to about 5 μg / mL. In some embodiments, the individual with overactive bladder is administered At least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or In some embodiments, the patient experiences at least about 50% relief from baseline symptoms for 6 weeks. In some embodiments, the individual has had a prior treatment for overactive bladder. In some embodiments, the individual is unresponsive to or has been treated with a prior therapy. In some embodiments, the individual is a human. In embodiments, the individual has idiopathic overactive bladder. have progressive sclerosis, Alzheimer's disease, Parkinson's disease, or have had a previous stroke I have done that before.

[0052] In another embodiment, the present application provides a method for administering an effective amount of trospium to a subject for at least about 42 days (e.g., for about Continuously administering the compound to the bladder of an individual for 42, 56, 70, or 84 days; A method of treating overactive bladder is provided, the method comprising: providing an individual with an antecedent treatment; and providing the individual with a response to the antecedent treatment. In some embodiments, trospium is administered for at least about 56 days. In some embodiments, trospium is administered for at least about 84 days. In some embodiments, trospium is administered for at least about 100 days. In some embodiments, the prior treatment is oral therapy. In some embodiments, trospium is administered by Approximately 1mg / day to 100mg / day, approximately 1mg / day to 20mg / day, approximately 2mg / day to 10mg In some embodiments, the urinary Trospium concentrations range from about 0.1 μg / mL to about 20 μg / mL while trospium is being administered. g / mL, approximately 1μg / mL to approximately 10μg / mL, approximately 2μg / mL to approximately 8μg / mL, approximately 3 1 μg / mL to about 7 μg / mL, or about 3 μg / mL to about 5 μg / mL. In embodiments, trospium is administered continuously or intermittently. , individuals with overactive bladder should be treated with trospium for at least about 7 days, 2 weeks, or more after trospium administration is completed. , at least about 50% relief of baseline symptoms for 3, 4, 5, or 6 weeks In some embodiments, the individual is a human. The body has idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, amyloidosis, bladder syndrome, idiopathic overactive bladder, idiopathic urinary tract infection ... have Alzheimer's disease, Parkinson's disease, or have previously had a stroke do.

[0053] In another aspect, the present application provides a method for administering trospium continuously and locally to the bladder for at least about 24 hours. A method for the maintenance treatment of overactive bladder in an individual is provided, comprising topically administering to the individual In some embodiments, the patient has had prior treatment for overactive bladder. This involves administering urethra locally to the bladder for at least about 24 hours every three months. In some embodiments, the maintenance period may consist of administering an effective amount of trospium as needed (prn) for a short period. In some embodiments, the symptom is Upon recurrence, administer an effective amount of trospium locally to the bladder for at least about 24 hours. In some embodiments, the individual experiences at least a 50% recurrence of baseline symptoms. When experiencing urinary incontinence, an effective amount of trospium is administered locally to the bladder for at least about 24 hours. In some embodiments, the prior treatment includes administering an effective amount of trospium or less. at least about 24 hours, at least about 42 days, at least about 56 days, or at least about 8 In some embodiments, the prior treatment is administered orally to the bladder for 4 days. In some embodiments, the individual is refractory to the prior therapy. In some embodiments, trospium is administered by using an intravesical delivery device. In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day, / day to 20mg / day, about 2mg / day to 10mg / day, about 4mg / day to about 8mg / day In some embodiments, the concentration of trospium in urine is During this period, the concentration ranged from about 0.1 μg / mL to about 20 μg / mL, and from about 1 μg / mL to about 10 μg / mL. mL, about 2 μg / mL to about 8 μg / mL, about 3 μg / mL to about 7 μg / mL, or about 3 μ In some embodiments, trospium is administered continuously or In some embodiments, the individual with overactive bladder is administered trospiu At least about 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks after completion of administration of In some embodiments, the individual experiences at least about 50% relief of baseline symptoms. The body is a human. In some embodiments, the individual has idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, Alzheimer's disease, Parkinson's disease. have had a stroke or have previously had a stroke.

[0054] Trospium is administered prn (as needed) for at least about 24 hours in the bladder. Methods for the maintenance treatment of overactive bladder in an individual comprising administering continuously and locally to the bladder In some embodiments, the individual has had a prior treatment for overactive bladder. In some cases, maintenance therapy may include trospium for at least about 42 days, at least about 56 days, or at least about 60 days. In some embodiments, the method further comprises administering the compound to the bladder locally for at least about 84 days. In some embodiments, the prior treatment is oral therapy. In some embodiments, administration of the vesical agent to the bladder is achieved by using an intravesical delivery device. In some embodiments, trospium is administered at a dose of about 1 mg / day to about 20 mg / day. 100mg / day, about 1mg / day to 20mg / day, about 2mg / day to 10mg / day, about 4mg In some embodiments, the urinary trospium concentration is The dose is about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL ~ approx. 10 μg / mL, approx. 2 μg / mL ~ approx. 8 μg / mL, approx. 3 μg / mL ~ approx. In some embodiments, the concentration is about 7 μg / mL, or about 3 μg / mL to about 5 μg / mL. Trospium is administered continuously or intermittently. In some embodiments, overactive bladder is treated with The individual is then administered trospium for at least about 7 days, 2 weeks, 3 weeks, 4 weeks, or 5 days after the administration of trospium is completed. Patients experience at least about 50% relief of baseline symptoms for one, five, or six weeks. In some embodiments, the individual is a human. In some embodiments, the individual is a In some embodiments, the individual has a condition such as multiple sclerosis, Alzheimer's disease, or , have Parkinson's disease or have previously suffered a stroke.

[0055] Also described herein is the administration of trospium continuously into the bladder for at least about 24 hours every three months. and topically administering to a subject a method for the maintenance treatment of overactive bladder in a subject. In some embodiments, the individual has received prior treatment for overactive bladder. The method comprises administering trospium for at least about 42 days, at least about 56 days, or at least about In some embodiments, the prior treatment comprises administering the drug topically to the bladder for 84 days. In some embodiments, the prior treatment is topical administration of trospium to the bladder. In some embodiments, the intravesical delivery device is used to deliver thoracic In some embodiments, trospium is administered at about 1 mg / day to about 100 mg / day. / day, about 1mg / day to 20mg / day, about 2mg / day to 10mg / day, about 4mg / day to about 8mg / day In some embodiments, the urinary concentration of trospium is While spirum is being administered, about 0.1μg / mL to about 20μg / mL, about 1μg / mL ~Approx. 10μg / mL, approx. 2μg / mL ~ approx. 8μg / mL, approx. 3μg / mL ~ approx. 7μg / m In some embodiments, the trospirus is about 3 μg / mL to about 5 μg / mL. In some embodiments, the drug is administered continuously or intermittently to an individual with overactive bladder. at least about 7 days, 2 weeks, 3 weeks, 4 weeks, or 5 weeks after trospium administration is completed or 6 weeks experience at least about 50% relief of baseline symptoms. In embodiments, the individual is a human. In some embodiments, the individual is a human suffering from idiopathic overactive bladder. In some embodiments, the individual has multiple sclerosis, Alzheimer's disease, Parkinson disease, or Have Son's disease or have previously had a stroke.

[0056] Trospium Trospium is a muscarinic receptor antagonist. Used to treat overactive bladder. It is known to be effective and has been formulated for oral administration (e.g., Sanctura (Allergan)). As with other oral muscarinic receptor antagonists, Patients often experience dose-limiting side effects or inadequate efficacy. Trospium is formulated for local delivery. Depending on the delivery mechanism, it may be provided in a solid or semi-solid form or in a liquid form. In some embodiments, devices, and systems described herein, trospium is In some embodiments, the thorax is provided in the form of a pharma- ceutical acceptable salt of thorax. A pharma- ceutically acceptable salt of trospium is trospium chloride. Other suitable forms of trospirus, including but not limited to polymorphs, hydrates, etc. The system is used.

[0057] In some embodiments, trospium is the compound 3-(2-hydroxy-2,2-di Phenylacetoxy)spiro[bicyclo[3.2.1]octane-8,1'pyrrolidine] The chemical formula is: is given by:

[0058] [ka]

[0059] Medication Regimen The following sections describe various aspects (embodiments) of administration and treatment regimens, All apply without exception to the methods described herein.

[0060] In various embodiments, trospium is administered at about 0.075 mg / day to about 1 mg / day over the course of treatment. 50 mg / day, for example, about 0.15 mg / day to 150 mg / day, about 1 mg / day to 100 mg g / day, about 1 mg / day to 20 mg / day, about 2 mg / day to 10 mg / day, about 4 mg / day to about It is administered locally (e.g., intravesically) to the bladder at a dose of 8 mg / day. Trospium is administered in doses of approximately 60 mg / day, 40 mg / day, or 20 mg / day over the course of treatment. / day, 15 mg / day, 10 mg / day, or 8 mg / day or less, administered topically to the bladder ( In some embodiments, trospium is administered at about 0.1 mg / mL. daily, 0.5 mg / day, 1 mg / day, 2 mg / day, 3 mg / day, or 4 mg / day or less The amount is administered locally (eg, intravesically) to the bladder.

[0061] In some embodiments, trospium is administered for at least about 24 hours, for 2 days, for 3 days, for 4 days, or for 5 days. or administered locally (e.g., intravesically) to the bladder of an individual for 1, 2, 3, 4, 5, 6, or 7 days. In some embodiments, trospium is administered at least about 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10, 11, 12, 13, 14, 15, or 16 hours, topically to the individual's bladder. In some embodiments, trospium is administered at least about The compound is administered locally (e.g., intravesically) to the individual's bladder for 6 weeks, or 42 days. In one embodiment, trospium is administered topically to the bladder of the individual for at least about 8 weeks, or 56 days. In some embodiments, trospium is administered intravesically (e.g., intravesically). In some embodiments, the bladder is administered topically for about 12 weeks, or 84 days. Spium is administered topically to the bladder of an individual (e.g., by administering urethral In some embodiments, trospium is administered at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 topically into the individual's bladder (e.g. In some embodiments, trospium is administered at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 26 Topically administered to the bladder of an individual for 0, 30, 40, 50, 60, 70, 80, 90, or 100 days. In some embodiments, trospium is administered intravesically for about 7 days. 14 days, 21 days, 28 days, 35 days, 42 days, 49 days, 56 days, 63 days, The urinary tract of the individual was examined for 70 days, 7784 days, 91 days, 98 days, 105 days, or 112 days. The compound is administered locally to the bladder (eg, intravesically).

[0062] In some embodiments, trospium is administered at a dose of less than every 1, 2, 3, 4, 5, or 6 weeks. In each case, the individual's bladder is exposed to the drug for approximately 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days. In some embodiments, trospium is administered at 1: At least about 24 hours, 2 days, 3 days, 4 days, or 5 days every 2, 3, 4, 5, or 6 months The compound is administered locally (e.g., intravesically) to the individual's bladder for one day, six days, or seven days. In some embodiments, trospium is administered at least about once every 1, 2, 3, 4, 5, or 6 months. or administered locally (e.g., intravesically) to the bladder of an individual for a period of one week, two weeks, three weeks, or four weeks. In some embodiments, trospium is administered at least every 2, 3, 4, 5, or 6 months. The compound is also administered locally (eg, intravesically) to the bladder of the individual for about five or six weeks.

[0063] In some embodiments, trospium is administered in an average amount of 1 mg / day to 100 mg / day, e.g. 1mg / day to 20mg / day, 2mg / day to 10mg / day, 4mg / day to about 8mg / day at most Approximately 7, 14, 21, 28, 35, 42 days, 49 days, 56 days, 63 days, 70 days , 77 days, 84 days, 91 days, 98 days, 105 days, or 112 days in the individual's bladder. In some embodiments, trospium is administered locally (e.g., into the bladder). The average dose is 1 mg / day to 100 mg / day, for example, 1 mg / day to 20 mg / day, 2 mg / day to 10 mg / day, 4 mg / day to about 8 mg / day up to about 6, 7, 8, 9, 10, 11, or 12 mg / day The compound is administered locally (eg, intravesically) to the individual's bladder for a period of months.

[0064] In some embodiments, trospium is administered at an average dose of about 10 mg / day for about 40-45 days ( The individual is administered locally (e.g., intravesically) to the bladder of the individual for a period of about 42 days. In terms of dosage, trospium is taken at an average dose of about 10 mg / day for about 80 to 87 days (e.g., about 84 days). The individual is administered locally (e.g., intravesically) to the bladder. Pium is administered only once.

[0065] In some embodiments, the concentration of trospium in the urine is about or at least about 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, In some embodiments, the concentration of trospium in urine is 6, 7, or 8 μg / mL. During administration of trospium, the concentration was approximately 2-3 μg / mL, approximately 3-4 μg / mL, and approximately 4 ~5 μg / mL, about 5-6 μg / mL, or about 6-7 μg / mL. In this form, the concentration of trospium in urine is approximately 0.01% while trospium is being administered. ~ about 100 μg / mL, for example, about 0.1 μg / mL to about 20 μg / mL, about 1 μg / mL L ~ approx. 10μg / mL, approx. 2μg / mL ~ approx. 8μg / mL, approx. 3μg / mL ~ approx. 7μg / In some embodiments, the urinary triglyceride concentration is about 3 μg / mL to about 5 μg / mL. The concentration of trospium should be at least about 0.01, 0.1 , 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 μg / mL. In this state, the average urinary concentration of trospium is approximately 0.0 1 to about 100μg / mL, about 0.1μg / mL to about 20μg / mL, about 1μg / mL to about 10 μg / mL, or about 2 μg / mL to about 8 μg / mL, about 3 μg / mL to about 7 μg / mL In some embodiments, the trospirus is about 3 μg / mL to about 5 μg / mL. The plasma concentrations of methionine were approximately 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, and 0.3. In some embodiments, the trospium concentration is less than 0.1, 0.2, or 0.1 ng / mL. In some embodiments, the plasma concentration of trospium is less than about 0.7 ng / mL. Plasma concentrations are undetectable.

[0066] In some embodiments, trospium is administered to the bladder via an intravesical delivery device. In some embodiments, the device contains between about 100 mg and 2000 mg of trospium. (For example, about 200 mg to about 1600 mg, about 400 mg to about 1200 mg, about 600 mg g to about 1000 mg, about 700 mg to about 900 mg, or about 850 mg of trospium) In some embodiments, the device contains at least about 1, 2, 3, 4, In some embodiments, the device is retained in the individual for at least 5 or 6 weeks. The device is retained in the individual for about 8, 10, or 12 weeks. It contains approximately 850 mg of trospium and is retained in the individual for approximately 42 days. In an embodiment, the device contains trospium in an amount of about 850 mg and provides the individual with approximately 84 days of therapy. Retained.

[0067] In some embodiments, the method comprises administering an effective amount of trospium periodically after the preceding treatment. and maintenance therapy, which includes administering the compound locally (e.g., intravesically) to the bladder of an individual. In some embodiments, maintenance therapy includes administering trospium as needed. In some embodiments, maintenance therapy includes administration every month, every other month, or every three months. In some embodiments, maintenance therapy includes trospium 1, 2, 3, 4 or 5 times a year. Some examples include administering the drug in doses of up to 1, 5, 6, 7, 8, 9, 10, 11, or 12 times. In embodiments, maintenance therapy consists of trospium phosphate on a schedule agreed upon by the individual and the physician. In some embodiments, the maintenance therapy comprises administering a medicament for which the overactive bladder symptoms return. In some embodiments, the method further comprises administering trospium when the patient is expected to Maintenance therapy is when symptoms recur, e.g., at least about 10% of baseline symptoms are reduced, 2 0%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% recurrence rate In some embodiments, the maintenance period includes administering trospium. Spium for at least about 24 hours, for 2, 3, 4, 5, 6, or 7 days. In some embodiments, the maintenance period includes administering trospium for at least Also about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or In some embodiments, the maintenance therapy includes administering trospium for 16 weeks. for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months In some embodiments, the maintenance therapy includes at least about 10 doses of trospium. including administration for 20, 30, 40, 50, 60, 70, 80, 90, or 100 days. In some embodiments, maintenance therapy includes trospium for about 7 days, 14 days, 21 days, or , 28 days, 35 days, 42 days, 49 days, 56 days, 63 days, 70 days, 77 days These include administering the drug for 84 days, 91 days, 98 days, 105 days, or 112 days.

[0068] In some embodiments, the prior treatment comprises administering an antimuscarinic agent. In some embodiments, the antimuscarinic agent is administered locally to the bladder of the individual (e.g., intravesically). In some embodiments, the antimuscarinic agent is administered orally to the individual for localized treatment. In some embodiments, the antimuscarinic agent is trospium. The prior treatment comprises administering an anticholinergic agent. In some embodiments, the prior treatment comprises administering: It involves administering trospium locally to the bladder for about 42 days or about 56 days.

[0069] In some embodiments, maintenance therapy is initiated immediately or within 24 hours of completion of the prior therapy. In some embodiments, the maintenance therapy is administered for at least about 1 h after the prior treatment is completed. In some embodiments, the maintenance therapy is initiated 2, 3, 4, 5, 6, or 7 days later. At least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, after completion of the preceding treatment In some embodiments, maintenance therapy is initiated 12 weeks after completion of prior therapy. At least about 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after do.

[0070] In some embodiments, the concentration of trospium in urine is determined based on prior and / or maintenance therapy. During the period, at least about 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 6, In some embodiments, the concentration of trospium in the urine is During the preceding treatment and / or maintenance period, about 0.01 μg / mL to about 100 μg / mL, for example, Approximately 0.1μg / mL to approximately 20μg / mL, approximately 1μg / mL to approximately 10μg / mL, approximately 2μg 1 μg / mL to about 8 μg / mL, and about 3 μg / mL to about 7 μg / mL. The mean urinary concentration of trospium was at least or about 0.01, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 μg / mL. In some embodiments, the average concentration of trospium in urine is During the period of chronic therapy, approximately 0.01 μg / mL to approximately 100 μg / mL, approximately 0.1 μg / mL to approximately 2 0 μg / mL, about 1 μg / mL to about 10 μg / mL, or about 3 μg / mL to about 8 μg / mL It's L.

[0071] In some embodiments, trospium is administered continuously. , trospium is administered intermittently.

[0072] In some embodiments, trospium is administered via an intravesical device. The chair is then cooled for at least about 24 hours, e.g., for at least about 1, 2, 3, 4, 5, 6, 7, 8 The drug remains in the bladder for periods of time such as 1, 2, 9, 10, 11, or 12 weeks. In embodiments, the intravesical device maintains a bladder function for at least about 1, 2, 3, 4, 5, or 6 months. In various embodiments, the intravesical device remains in the bladder for a period of about 24 hours to about 6 months, e.g. , Approx. 24 hours to 7 days, Approx. 24 hours to 2 weeks, Approx. 24 hours to 4 weeks, Approx. 24 hours to 6 weeks , about 24 hours to 8 weeks, about 24 hours to 10 weeks, about 24 hours to 12 weeks, etc. Therefore, the concentration of trospium in the bladder that produces a sustained, therapeutically effective concentration of trospium was determined. To achieve this, trospium may be released continuously or intermittently. In some embodiments, trospium is administered to the bladder for about 42 days. The drug is administered into the bladder for approximately 56 or 112 days.

[0073] In some embodiments, the mean total daily urinary recovery of trospium during the device indwelling time is: At least about 0.1, 0.5, 1, 1.5, 2, 2.5, or 3 mg / day. In some embodiments, the mean total daily urinary recovery of trospium during the time of device placement is about 30 , 18, 15, 12, 10, 9, or 8 mg / day or less. The mean total daily urinary recovery of trospium during the device placement period ranged from approximately 0.1 mg / day to approximately 30 mg / day. mg / day, about 1mg / day to about 25mg / day, about 2mg / day to about 10mg / day, about 3mg / day The dose is approximately 9 mg / day.

[0074] Patient population The individual treated with the methods described herein may be a mammal. , the individual is a human.

[0075] In some embodiments, the individual has idiopathic overactive bladder.

[0076] In some embodiments, the individual has had prior treatment for overactive bladder. In some embodiments, the individual is refractory to a prior treatment. In some embodiments, the individual has severe overactive bladder. In some embodiments, the individual is unresponsive to a prior treatment. In some embodiments, the individual is currently undergoing a prior treatment. Upon completion, the individual has a recurrence of baseline symptoms, e.g., the individual has a recurrence of baseline symptoms At least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 9 In some embodiments, the prior treatment is oral therapy. In embodiments, the prior treatment is a topical treatment. In some embodiments, the agent is Botox. trademark), VEScare® (solifenacin succinate), and Detro LA (tolterodine tartrate). In embodiments, the prior treatment includes administering an anticholinergic agent.

[0077] In some embodiments, the individual has not had a prior treatment for overactive bladder.

[0078] In some embodiments, the individual is not eligible for oral treatment. For example, the individual is unable to discontinue treatment. In some embodiments, the individual is elderly or infirm. In some embodiments, the oral treatment comprises an anticholinergic agent. The oral treatment includes an antimuscarinic agent. In some embodiments, the agent is Botox (R (trademark), VEScare® (solifenacin succinate), and Detrol® (tolterodine tartrate).

[0079] In some embodiments, the individual has a neurological condition. In some embodiments, the neurological condition is multiple sclerosis. In some embodiments, the neurological condition is Alzheimer's disease. In some embodiments, the individual has suffered a stroke.

[0080] In some embodiments, the individual has symptoms of overactive bladder with a predominant urge component; For example, over 50% of overactive bladder symptoms are associated with urgency (as opposed to frequency). In some embodiments, the individual has at least about 1, 2, 3, 4, 5, 6, 7, 8, Symptoms of overactive bladder with a predominant urge component lasting 9, 10, 11, or 12 weeks In some embodiments, the individual has at least about 3, 4, 5, 6, 7, 8, 9, 10 have symptoms of overactive bladder with a predominant urge component for a period of 11, 12, or 24 months. In some embodiments, the individual receives the drug about 4, 5, 6, 7, 8 or more times per 24 hours. In some embodiments, individuals are assessed for urgency-related symptoms in a 3-day diary. Have at least about 2, 3, 4, 5, or 6 urinary incontinence episodes associated with In some embodiments, the individual receives at least 1, 2, or 3 daily doses of has three episodes.

[0081] In some embodiments, the individual has urinary incontinence or urge incontinence.

[0082] In some embodiments, the individual receives less than about 300 mL (e.g., about 300 mL, 250 mL, 00 mL, 150 mL, or less than 100 mL).

[0083] In some embodiments, the individual is female. In some embodiments, the individual is male. be.

[0084] In some embodiments, the individual is about 40 to about 70 years old. The individual is at least about 40, 45, 50, 55, 60, 65, or 70 years of age. In some embodiments, the individual is no older than about 70, 65, 60, 55, 50, 45, or 40 years of age. be.

[0085] overactive bladder In some embodiments, the overactive bladder is associated with a neurological condition. In embodiments, the neurological condition is multiple sclerosis. In some embodiments, the neurological condition is Parkinson's disease. In some embodiments, the neurological condition is a previous stroke.

[0086] In some embodiments, the overactive bladder is not associated with a neurological condition.

[0087] Endpoints In some embodiments, the methods provided herein include treating symptoms in an individual with overactive bladder. and delivering trospium locally to the bladder for at least about 24 hours. In some embodiments, the individual receives baseline trospium therapy during or after completion of the administration of trospium. At least about 10%, 20%, 30%, 40%, 50%, 60%, 70% of line symptoms, In some embodiments, symptom relief includes relief of urgency and / or symptoms of 80% or 90%. In some embodiments, symptom relief includes a reduction in the frequency and / or severity of abnormal urges. In some embodiments, the urgency and / or frequency is relieved during or after administration of trospium. At least approximately 10%, 20%, 30%, 40%, 50%, or 60% above baseline after completion of the study. In some embodiments, symptom relief is reduced by 60%, 70%, 80%, or 90%. urinary incontinence and / or urge incontinence (e.g., 1 daily incontinence episode or urinary incontinence for 3 days or less) In some embodiments, the reduction of urinary incontinence and / or urge incontinence (e.g., episodes) is achieved. For example, 1-day urinary incontinence episode or urinary incontinence episodes lasting 3 days or less should be treated with trospium. At least about 10%, 20%, 30%, 40% reduction in baseline symptoms during or after completion of , 50%, 60%, 70%, 80%, or 90% reduced. Symptom relief is at least about 1, 2, 3, 4, 5, 6, or 7 days after completion of administration of trospium. In some embodiments, symptom relief is extended for 10 days after completion of administration of trospium. extended for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks In some embodiments, symptom relief occurs for at least about 3 days after completion of administration of trospium. , 4, 5, 6, 7, 8, 9, 10, 11 or 12 months.

[0088] In some embodiments, the individual is administered a daily void during or after completion of administration of trospium. In some embodiments, the daily voiding episodes are reduced by A reduction of at least about 2.5%, 5%, 7% or 8% from baseline symptoms during or after completion of treatment with UM. In some embodiments, the reduction is a reduction of 5% or 10% in the administration of trospium. After completion of the test, the test is extended for at least about 1, 2, 3, 4, 5, 6, or 7 days. In some embodiments, the reduction is at least about 1, 2, 3, 4, 5, 6 hours after completion of administration of trospium. , 7, 8, 9, 10, 11, or 12 weeks. , at least about 3, 4, 5, 6, 7, 8, 9, 10, 11 days after completion of trospium administration , or extended for 12 months.

[0089] In some embodiments, the individual urinates once during or after completion of administration of trospium. In some embodiments, the increased amount of urine output per urination The increase is at least about 2.5% from baseline symptoms during or after completion of trospium treatment. %, 5%, 7.5%, 10%, 20%, 25%, 30%, 35%, or 40%. In some embodiments, the increase is at least about 1, 2, 3 or 4 days after completion of administration of trospium. In some embodiments, the increase is extended by trospium at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or In some embodiments, the increase is after completion of administration of trospium. The extension is for at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.

[0090] In some embodiments, the present invention provides a method for administering an effective amount of trospium to a subject for at least about 24 hours. and administering the compound to the bladder. In some embodiments, the individual's quality of life score is improved. The study found that individuals had a higher quality of life score after trospium compared to their pre-treatment quality of life scores before topical therapy with trospium. Improved quality of life scores at least approximately 24 hours after completion of topical administration of pium In some embodiments, the quality of life score is based on the individual's ability to, for example, live a full life without time Some time, some time, a long time, most of the time, and all of the time In some embodiments, the score includes a score based on the frequency with which the patient experienced one or more events during the course of the event. Elephants suffer from a sudden need to urinate with little or no warning. In an embodiment, the event includes suffering from an occasional small amount of urine leakage. In some embodiments, the event comprises suffering from nocturnal urination. In some embodiments, the symptoms include waking up at night due to the need to urinate. In some embodiments, the event includes suffering from urinary leakage associated with a strong urge to urinate. reported that individual quality of life scores improved by approximately 10%, 20%, 30%, and 40% after topical trospium administration. In some embodiments, the individual Physical quality of life scores were evaluated for at least 1 week after topical trospium administration was completed. At least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 10 weeks, at least 11 weeks , or improved for at least 12 weeks.

[0091] In some embodiments, the present invention provides a method for administering an effective amount of trospium to a subject for at least about 24 hours. In one embodiment, a method for improving an individual's quality of life score is provided, comprising administering the compound to the bladder. In some embodiments, the individual is administered a pre-existing condition prior to topical treatment with trospium. Compared with quality of life scores, at least approximately 24 hours after completion of topical trospium administration Afterwards, the patient has an improved quality of life score. In some embodiments, the quality of life score is ,An individual may, for example, be in a state where,no time, a small amount of time, some amount of time, a large amount of time,,most of the time It includes scores based on the frequency with which one or more events were experienced over a period of time, such as over time, over a period of time, or over all time. In some embodiments, the event is a sudden urge to urinate with little or no warning. In some embodiments, the event includes suffering from occasional small amounts of urine leakage. In some embodiments, the event comprises suffering from nocturnal urination. In some embodiments, the event is being bothered by waking up at night due to the need to urinate. In some embodiments, the event includes suffering from urine leakage associated with a strong urge to urinate. In some embodiments, the individual's quality of life score is determined based on the daily dose of topical trospium. Approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% improvement after In some embodiments, the individual's quality of life score is evaluated after topical trospium administration is completed. At least one week, at least two weeks, at least three weeks, at least four weeks after the completion of the At least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least is improved for at least 10 weeks, at least 11 weeks, or at least 12 weeks.

[0092] In some embodiments, trospium is administered to the individual for at least about 24 hours. and a method for reducing distress associated with a bladder condition in an individual, the method comprising delivering to the bladder In some embodiments, the individual's distress score is reduced. So, the distress score was higher after topical trospium therapy compared to before topical trospium therapy. The reduction is at least about 24 hours after administration is completed. The quality score of a given individual may be determined based on the amount of time spent on that individual, e.g., no time, a little time, some time, a lot of time, Based on how often one or more events were experienced during a period of time, such as most of the time and all of the time. In some embodiments, the event may include a score for a number of events, such as running to a restroom in a public place, In some embodiments, the event includes determining whether the individual's bladder symptoms are: Includes bladder symptoms that affect how often an individual feels that there is something wrong with them. In some embodiments, the event comprises bladder symptoms that interfere with restful nighttime sleep. In this case, the event is one that makes an individual feel dissatisfied or annoyed about the amount of time they spend in the bathroom. In some embodiments, the event includes bladder symptoms that cause the individual to engage in an activity (e.g., Some include bladder symptoms that may cause you to avoid activities such as walking, running, or hiking. In some embodiments, the event comprises a bladder symptom that awakens a sleeping individual. In the form of a bladder symptom that causes an individual to reduce their physical activity (exercise, sports, etc.) In some embodiments, the event may cause the individual to have problems with their partner or spouse. In some embodiments, the event includes a bladder symptom that causes discomfort while traveling with others. This includes bladder symptoms which can cause embarrassment to the individual as they have to visit the bladder. In some embodiments, the event is a bladder symptom that affects the individual's relationships with family and friends. In some embodiments, the event includes embarrassment caused by an individual's bladder symptoms. In some embodiments, the event includes an individual's bladder symptoms being diagnosed with a bladder disorder at the first visit to the individual. In some embodiments, the system may have the user search for the nearest restroom upon arriving at a location where the user is to rest. Individuals' trouble scores increased by approximately 10%, 20%, 30%, and 40% after topical trospium administration. In some embodiments, the individual's symptoms are improved by 50%, 60%, 70%, or 80%. The score was evaluated at least 1 week after topical trospium administration was completed and at least 2 weeks after at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 10 weeks, at least 11 weeks, or The improvement will last for at least 12 weeks.

[0093] In some embodiments, the quality of life score [i.e., health-related quality of life (HRQL The symptom severity converted score and distress score (i.e., symptom severity converted score) were calculated via a questionnaire. The results are calculated from the subject's self-evaluation. An example of the questionnaire is shown in FIG. 13 to FIG. 14. The titration should be performed prior to (e.g., immediately before) trospium administration to establish a baseline. Assessments can also be made at different times during or after trospium administration. Cut.

[0094] For example, a quality of life score can be calculated from the raw scores in Figure 14 as follows: The raw score was the sum of the scores from items 1 to 13. Quality of life score = (maximum possible The maximum possible score is 7. 8, with a possible raw score range of 65. Higher quality of life scores indicate a better quality of life. Note that this shows that

[0095] The distress score can be calculated from the raw scores in Figure 13 as follows: , the sum of scores from items 1 to 6. Distress score = (actual raw score - lowest possible Raw score) / possible raw score range × 100, where minimum possible raw score = 6, and possible The raw score range was 30. Higher distress scores indicated greater symptom severity or distress. Note that scores indicate minimal symptom severity, with lower scores indicating minimal symptom severity.

[0096] In some embodiments, trospium is administered via an intravesical device described herein. In some embodiments, the individual has a high tolerance to the device. (e.g., less than about 30%, 20%, 15%, 10%, 5%, or 2% of individuals (requiring removal of the device prior to completion of scheduled therapy).

[0097] In some embodiments, the method does not cause a significant level of an adverse event in an individual. Exemplary adverse events include urinary tract infection (UTI), bladder pain, hematuria, sinusitis, and bladder discomfort. In some embodiments, about 50%, 40%, 30%, or 40% of individuals experience %, 25%, or less than 20% will develop a UTI during treatment. About 50%, 40%, 30%, 25%, or less than 20% of individuals experience bladder pain during the treatment period. In some embodiments, about 50%, 40%, 30%, 25%, or 20% of individuals develop Less than 40% of individuals develop hematuria during treatment. 0%, 30%, 25%, or less than 20% of patients develop sinusitis during treatment. In embodiments, less than about 50%, 40%, 30%, 25%, or 20% of the individuals are During this time, I develop bladder discomfort.

[0098] In some embodiments, the bladder post-void residual (PVR) of an individual is determined by the administration of trospium. After administration, at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% In some embodiments, the reduction is at about 7 days, 21 days, or 30 days after administration of trospium. , or observed within 35 days.

[0099] delivery I. Intravesical Devices a. Device shape In some embodiments, the methods provided herein include administering a bladder injection using an intravesical device. In some embodiments, the method includes locally delivering an effective amount of trospium to the bladder. The intravesical device includes a deployment configuration and a retention configuration. For example, the device may be configured to A relatively straight or non-coiled configuration suitable for insertion through the bladder of an individual. and a retention shape suitable for retaining the device within the bladder. For purposes of this disclosure, a "relatively expanded shape" or a "relatively large profile shape" may be used. Terms such as "retention shape" or "retention shape" generally refer to the ability to retain the device in its intended implanted position. "Upper lip" means any shape suitable for holding the device in the bladder, including any shape suitable for holding the device in the bladder. These include coil shapes or other coil shapes (e.g., bi-elliptical or overlapping coils). A retention shape is one in which the device is taken up in the urine when the individual urinates and is not excreted. Similarly, terms such as "relatively small external shape" or "configuration shape" are generally used to refer to means any shape suitable for placing a drug delivery device in the body, e.g., a catheter. A catheter, cystoscope, or other placement instrument positioned within the urethra or bladder, e.g. Suprapubic bladder used to drain urine from the bladder in individuals with significant urinary flow obstruction Fistula or suprapubic catheter (vesicostomy or epicystostomy) Straight shape suitable for placing devices through the working channel of the endoscopic tomy In some embodiments, the drug may be in a shape such as, but not limited to, a round or elongated shape. The agent delivery device may naturally assume a relatively expanded shape and is suitable for insertion into the body. The outer shape of the outer shell can be deformed into a relatively small shape manually or with the aid of an external device. The external device may be an introducer configured for transurethral insertion. Once placed, the intravesical device The device can spontaneously or naturally return to its original relatively expanded shape and be retained within the body. In some embodiments, the device behaves like a spring and responds to a compressive load. deforms (e.g., causes the device to deform into a deployed shape) but spontaneously dissipates when the load is removed Will retain its shape when returned to its original position.

[0100] In some embodiments, the deformation function of the intravesical device described in the previous paragraph is No. 2012 / 0203203, which is incorporated herein by reference. No. 13 / 0158675, No. 2015 / 0360012, No. 2015016517 7, 2015 / 0165178, 20160199544, and International Patent Nos. 2014 / 145638, 2015200752, and 2011 / 03 A shape-retaining frame (i.e., a "retaining frame"), such as that disclosed in US Pat. No. 5,855, is used. In some embodiments, the device may be provided by inclusion in the device. The retaining frame may include a lumen in which an elastic wire, e.g., a superelastic composite such as Nitinol, is inserted. A retaining frame, which may be gold, is secured to the support. The retaining frame may be, for example, any of the materials described in the previously incorporated patents. In a holding shape such as a "pretzel" shape or another coil shape such as that disclosed in the application. In particular, the retention frame may be configured to return to its original position spontaneously when placed inside the body, for example, in the bladder. The device may be retained within the body. The retention shape may be such that the device is taken up in urine when the individual urinates. For example, the retention frame allows the device to have a relatively small profile. The device is then introduced into the body in a relatively expanded shape once inside the body. This allows the bladder to return to its original position and withstand the expected forces, such as detrusor contraction and fluid forces associated with urination. In response, elastic limits and elastic moduli prevent the device from assuming a relatively small profile within the body. Thus, the device, once deployed, may be retained within the individual's bladder, Limiting or preventing accidental releases.

[0101] In some other embodiments, the deformation function of the intravesical device is, for example, as described in WO 2005 / 023666. As described in US Pat. No. 16 / 172704, the at least partially thermally shaped elastic body This can be achieved by forming the device housing from a conductive polymer.

[0102] The material used to form the device body (i.e., housing) determines the placement and retention shape. The device may be at least partially elastic or flexible to allow the device to be moved between the When the device is in the retained configuration, the retaining frame portion is positioned inside the drug reservoir portion. In other cases, the retaining frame portion may tend to be positioned inside the drug reservoir portion, The material used to form the device body is water permeable. Thus, when the device is placed in the bladder, it can absorb solubilizing fluid (e.g., urine) ) enters the drug reservoir portion and is contained in the drug reservoir, The drug may be a chemotherapeutic agent, an immunomodulatory agent, an additional therapeutic agent, a functional agent, or a combination thereof. For example, silicone or another biocompatible elastomeric material can be used. In other embodiments, the device body may be at least partially made of a water-impermeable material. It may be formed.

[0103] In some embodiments, the device body is made of an elastic, biocompatible polymeric material. The material may be non-absorbable or absorbable. Examples of non-absorbable materials include poly( ether), poly(acrylate), poly(methacrylate), poly(vinylpyrrolidone) ), poly(vinyl acetate), poly(urethane), cellulose, cellulose acetate, poly(siloxane) Poly(oxane), poly(ethylene), poly(tetrafluoroethylene), and other fluorinated poly Exemplary absorbents include synthetic polymers selected from the group consisting of poly(siloxanes), poly(ethylene glycol) copolymers, and poly(ethylene glycol) copolymers. Absorbent materials, specifically biodegradable or biodegradable polymers, include poly(amides), ... Poly(esters), poly(ester amides), poly(anhydrides), poly(ortho esters), Polyphosphazenes, pseudopoly(amino acids), poly(glycerol-sebacate), poly( lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), poly(caprolactone) Poly(caprolactone) (PC)-introduced bodies, amino alcohol-based poly(ester acetate) Poly(ethylene glycol) (PEA) and poly(octanediol citrate) (POC), as well as other curing agents. The synthetic polymers selected from the group consisting of PC-based polymers and PC-based polymers are bioabsorbable elastomers. In order to obtain rubber-like elasticity, lysine diisocyanate or 2,2-bis(e-caprolactone) Copolymers, mixtures, and Combinations of the above materials may also be used.

[0104] In some embodiments, the device body is made of a material selected from the group consisting of silicone, thermoplastic polyurethane, ethylene, and the like. In some embodiments, the polymer may comprise ethylenediaminetetraacetate (EDTA), ethylenediaminetetraacetate (EVA), or a combination thereof. The device body comprises two different thermoplastic materials, one of which is a hydrophilic thermoplastic polymer. The urethane is drug-permeable, and the other is drug-impermeable. , hydrophilic polyurethane, hydrophilic polyester, and hydrophilic polyamide The device body may be a casing as described in U.S. Patent Publication No. 2010 / 0136644, which is incorporated herein by reference. As described in PCT application Ser. No. 6 / 0310715, one or more of these materials may be used. The extrusion or co-extrusion process may comprise an annular tube formed by an extrusion or co-extrusion process.

[0105] b. Drug core / fill In embodiments in which trospium is delivered from an intravesical drug delivery device, the composition comprises The device may be adapted to a particular mechanism for controllably releasing the composition into the fluid (e.g., urine) in the bladder. In some embodiments, the composition may be contained within the device in a variety of forms, including solid, It is provided in a semi-solid or other non-liquid form and thus advantageously can be used to prepare the device prior to use. This can facilitate stable storage of the product, which is advantageous when the composition is contained in the form of a liquid solution. This may allow the composition load of the device to be stored in a smaller volume than would otherwise be possible. In some embodiments, the non-liquid form is a tablet, granule, pellet, powder, semi-solid (e.g. , ointment, cream, paste, or gel), capsule, and combinations thereof In one embodiment, the composition is as described in U.S. Pat. It comes in the form of multiple tablets, including mini tablets.

[0106] For example, trospium may be present as a suspension, solution, colloid, micelle, or in an oily or aqueous medium. The formulation may take such forms as emulsions, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Alternatively, the active ingredient may be dissolved in a suitable vehicle, e.g., sterile, pyrogen-free, prior to use. For aqueous formulations, by aseptic isolation of a sterile solid or by lyophilization from a solution. It may be in the form of a powder obtained by

[0107] In one embodiment, the trospium is released from a release opening in the device housing. The drug is formulated with one or more excipients, including a viscosity enhancer to control the release of the drug. In this embodiment, the device reservoir contains both trospium and a viscosity enhancing agent. They are not coformulated, but instead are provided in separate regions within the reservoir, e.g., as separate tablets. Suitable polymers include, but are not limited to, polyethylene oxide (PEO). Viscosity enhancing agents are known in the pharmaceutical art. In some variations of the embodiment, the viscosity The enhancer may be provided, for example, formulated with, for example, urea or another penetrant.

[0108] In one embodiment, trospium is delivered to the individual's bladder along with a solubility enhancer. In an embodiment, the solubility enhancer is urea. In one embodiment, the urea is in tablet or other solid form. and is loaded with trospium into the drug reservoir of the intravesical drug delivery device. Urea also acts as an osmotic agent to facilitate the generation of osmotic pressure within the drug reservoir, depending on the device. In certain embodiments, the trospium and osmotic agent may function as As described in incorporated International Publication No. WO 2015 / 026813 (Lee et al.), Separate fills (i.e., powders, tablets, or other individual forms).

[0109] In some embodiments, the device may include a drug reservoir lumen. In some of the configurations, each drug reservoir lumen contains one or more drug tablets or other solid objects. In one embodiment, the device may hold multiple separate drug reservoirs. The lumen holds about 10 to 100 cylindrical pharmaceutical tablets (e.g., mini tablets). In an embodiment, the mini-tablets are each, for example, about 1.0 to about 3 mm, such as about 1.5 to about 3.1 mm. 0.3 mm in diameter and a length of about 1.5 to about 4.7 mm, e.g., about 2.0 to about 4.5 mm In some other embodiments, the drug reservoir lumen may have a powder or granular form. Contains trospium.

[0110] In some embodiments, the intravesical device contains and releases a functional agent along with trospium. The functional agent may facilitate the release of the drug from the device and / or reduce the amount of drug in urine in the bladder. The functional agent may help stabilize (i.e., slow the degradation) of lospium. For example, the functional agent may reduce the amount of lospium in urine. If proteolytic degradation of trospium is a concern, an antiprotease may be included.

[0111] c. Drug housing Release of trospium from the intravesical devices described herein occurs via different mechanisms of action. In various embodiments, the drug can be delivered through the walls of the drug housing. By diffusion through one or more defined openings in the wall of the drug housing. The drug is then injected into one or more of the temporarily formed vesicles by osmotic pressure through an opening in the drug housing. By osmotic pressure through the microchannels, by erosion of the formulation upon contact with urine in the bladder, or a combination thereof may be released from the intravesical drug delivery device. In some embodiments, drug release is achieved by passing drug-permeable polymers that define a portion of the device housing. In one embodiment, the drug is regulated by drug diffusion through / from the matrix components. In, the device comprises a drug-permeable polymer component.

[0112] The size of the housing, such as the wall thickness, will depend, among other factors, on the drug (and any other substances present) that will be contained therein. the volume of the formulation (functional agent, if any), the desired delivery rate of the agent from the device body / housing; the intended implantation site of the device within the body, the desired mechanical integrity for the device; The desired release rate or permeability to water and urine, the desired induction time before the onset of the initial release, and The housing may be selected based on the desired method or route of insertion into the body. In an embodiment, the pipe wall thickness may be determined based on the mechanical properties and water permeability of the pipe material. However, a tube wall that is too thin may not have sufficient mechanical integrity, while a tube wall that is too thick may The walls may experience undesirably long induction times for initial drug release from the device; and and / or have sufficient flexibility to allow delivery through the urethra or other narrow body lumens. This is because there are times when this is not the case.

[0113] In some embodiments, the housing comprises an elongated ring having an inner diameter of about 2 mm to about 5 mm. The drug, and if present, the functional agent, may be substantially the same diameter as the inner diameter of the elongated annular tube. In some embodiments, the housing may be a solid tablet having the same diameter. One or more first units (e.g., tablets) containing a drug and a device for facilitating release of the drug or and / or one or more second functional agents that promote stabilization of trospium in urine in the bladder. One or more of the tablets of the first unit are The lumen of the tube may be filled to a length of about 1 cm to about 3 cm, and one of the tablets of the second unit may be One or more may fill a length of about 10 cm to about 15 cm of the lumen of the tube. The ratio of the volume of the first unit to the volume of the second unit is about 0.05 to about 0.5. Other lengths and ratios of agent packing are envisioned.

[0114] In some embodiments, the housing has a wall thickness of about 0.1 mm to about 0.2 mm. The housing material may be an elongated annular tube having a wall thickness of 4 mm. The housing material may include a synthetic elastomer. For example, the wire may be selected to have a durometer of 25A, 50A, 65A, 70A, or 80A. It is okay to do so.

[0115] In various embodiments, the intravesical device is a bladder cancer treatment device as described in the methods provided herein. To achieve a concentration of drug in the bladder that produces a sustained therapeutically effective concentration of drug in urine in the bladder In certain embodiments, the intravesical device may release the drug continuously or intermittently. , 1 mg / day to 1000 mg / day, for example 20 mg / day to 300 mg / day, or 25 mg Trospium may be released in amounts of 0.1 mg / day to 300 mg / day. The release rate is provided over the treatment period described herein. In certain embodiments, These release rates are provided over a treatment period of 14 to 21 days.

[0116] d. Osmosis and diffusion systems Following in vivo deployment, the device releases trospium. The outflow is caused by an osmotic pressure gradient between the inside and outside of the device, and by the presence of one or more oliguria in the device under osmotic pressure. Release may occur due to drug passing through vesicles or through pores. Release may also occur by diffusion. , whereby the drug is delivered to the device due to a drug concentration gradient between the inside and outside of the device. through one or more orifices or passage holes in, and / or through a drug-permeable wall of, the device; A combination of these release modes within a single device is possible, and in some embodiments In this mode, an overall drug release profile cannot be easily achieved by any of the individual modes. This is preferred for achieving a profile.

[0117] In some embodiments where the device contains a drug in solid form, elution of the drug from the device This occurs after dissolution of the drug within the device. Body fluids enter the device, come into contact with the drug, and dissolve it. The drug is then solubilized and the dissolved drug diffuses out of the device or is absorbed under osmotic or diffusive pressure. This "dissolved drug" flows from the device via the and may include micro- and nano-scale particles of the drug in suspension remaining after, e.g. , may be expelled from the device through an opening in the device housing. For example, the drug may be solubilized upon contact with urine in the bladder. The water-permeable wall of the coating is permeable to drugs in aqueous solution, and the solubilized drug is absorbed into the wall. When the device is placed in the individual's bladder, the release occurs via the bladder wall, also referred to herein as "transmural diffusion." Once placed, urine will seep through the wall and enter the reservoir, trapping trospium, if present, and In some embodiments, the agent is then distributed inside and outside the device. Due to a drug concentration gradient between the two compartments, the drug diffuses directly through the wall at a controlled rate. For example, The housing and / or any water or drug permeable wall portions may be made of silicone, thermoplastic polymer, Urethane, ethylene-co-vinyl acetate (EVA), or a combination of these. That's fine.

[0118] In some embodiments, the intravesical device comprises: (i) a reservoir defined within the body; A body having a wall bounding the water-permeable portion, the wall having a preformed through hole, (ii) a reservoir disposed within the reservoir; and (iii) a constraining plug closing the opening of the body and contacting the elastic portion of the body. wherein the opening is in fluid communication with the reservoir and the water-permeable portion of the wall prevents water from entering the device. and configured to allow the drug to contact the formulation in the reservoir, and to release the drug from the device. The release of trospium is (a) through preformed holes in the wall. (b) in a reservoir of hydrostatic pressure effective to form one or more microchannels. Upon generation of the pressure, one or more micro-pumps are formed between the elastic portion of the body and the restraining plug, the micro-pumps extending to the opening. release of trospium via the transient formation of chloroform channels; and a constraining plug. The formulation may be in the form of a plurality of tablets, the body being a silicone tube. These embodiments may be in the form of: / US18 / 16463.

[0119] In a first embodiment, as shown in Figures 1A-1D, the drug delivery device described herein Device 50 is disclosed in U.S. Patent Application Publication No. 2005 / 0133634, which is incorporated herein by reference in relevant part. As described in US Pat. No. 2016 / 0008271 (Lee), the distal opening of the device body Elastic portions (multiple) of the device body 52 may be provided to allow drug release through the mouth (s). The one or more captive plugs 56 contact the captive plugs 54. However, U.S. Pat. No. 2016 / 0008271 (Lee) without an orifice (i.e. a pre-defined opening system) In contrast to a system without a device, in certain embodiments, as shown in FIGS. 2 and 3A, The device is fitted with at least one preformed through hole (s) disposed in the wall of the device body 52. 3, includes a nozzle hole 66 (i.e., an orifice).

[0120] Thus, in certain embodiments, as shown in FIGS. 1-4, drug delivery device 5 0 is a body 52 having a wall bounding a reservoir 60 defined within the body 52. The wall is provided with at least one preformed through hole 66 and has a water permeable portion. The body 52 includes an elastic portion 54, and the body 52 includes a formulation 58 containing a drug. The formulation 58 is disposed in a reservoir 60. The formulation 58 and the opening of the body 52 are at least one captive plug 56 that closes and contacts the resilient portion 54 of the body 52; The opening includes at least one captive plug 56 in fluid communication with a reservoir 60. The water permeable portion 64 of the wall allows water to enter the drug delivery device 50 and be disposed within the reservoir 60. and configured to allow the drug 58 to be contacted with the drug formulation 58 from the device 50. The release occurs through (i) at least one preformed through hole 66 in the wall (i.e., an opening, (ii) releasing a drug 58 through one or more microchannels. Upon generation of hydrostatic pressure effective to form 62, elastic portion 54 of body 52 and at least one The transition of one or more microchannels 62 extending to the opening between the confining plug 56 and the and releasing the drug via formation of a vesicle. In these embodiments, the constraining plug 56 is partially or completely inserted into the distal opening of the device 50. Such a system provides consistent and reproducible drug release profiles. While providing a therapeutic effect, it also beneficially prevents drug release when the perforations are partially or completely blocked. It has been found that the device provides a relief valve system that Hydrostatic pressure in the drug reservoir creates a constrained plug (or multiple constrained plugs) that results in point release through the constrained plug. through a preformed orifice unless and until a threshold pressure of For example, the at least one preformed through hole may be operable to release the drug. Release of the drug via the may be osmotically driven.

[0121] In a second embodiment, as shown in Figures 5-6, the drug delivery device described herein The device 50 includes one or more restraining plugs that contact the elastic portion(s) 54 of the device body 52. 56, including a sealed distal end (shown sealed with adhesive 70). , preformed release pores within the device body 52 (e.g., sidewalls) adjacent the constraining plug 56 Allows drug release through port(s) 68. Elastic portion 54 (FIGS. 9-10) The electrodes may be at or near the end of the device 50 (as shown in FIG. 1), or may be located at or near the end of the device 50. The restraints may be disposed along the length of the device, for example at or near the center of the device. The retraining plug(s) 56 may be one or more preformed plugs within the device body 52. The captive plug(s) may be located adjacent the discharge port(s) 68. ) 56 is preformed when the threshold hydrostatic pressure in the drug reservoir 60 has not been reached. 5. Covering and effectively closing the ejection port(s) 68. In such an embodiment, The restraining plug 56 and elastic portion 54 of the device are adapted to release the drug reservoir 60 when the drug reservoir 60 reaches a threshold hydrostatic pressure. One or more microchannels 62, which may be formed transiently at times, may be preformed from the drug reservoir 60. 1. The same as described above and U.S. Pat. No. 5,993,313, except that the nozzle extends to the outlet port(s) 68 formed therein. The composition may be similar to that described in Patent Application Publication No. 2016 / 0008271 (Lee). stomach.

[0122] Thus, in certain embodiments, as shown in FIGS. 5-6, drug delivery device 5 0 is a tubular body 52 having a wall bounding a reservoir 60 defined therein. The wall has a water permeable portion 64 and an elastic portion 54, and at least one preformed release A tubular body having a port 68 (e.g., a through hole, an opening, an orifice, a slit) disposed therein. a body 52 and a drug-containing formulation 58, the formulation 58 being disposed in a reservoir 60; The water permeable portion 64 of the wall allows water to enter the drug delivery device and disperse the formulation 58 located in the reservoir 60. The formulation 58 contacts the elastic portion 54 of the body 52, allowing the formulation 58 to contact the elastic portion 54 of the body 52 at least At least one preformed discharge port 68 is secured within the reservoir 60 adjacent the reservoir 60. At least one of the captive plugs 56 includes one or more micro-captive plugs 56. Upon generation of hydrostatic pressure within the reservoir 60 effective to form a cross channel 62, the elasticity of the body At least one preformed gap between the portion 54 and the at least one constraining plug 56. The transient formation of one or more microchannels 62 extending to the discharge port 68 The release of the drug from the device is controlled through at least one preformed release port 68. and at least one constraining plug 56 that controls the flow of the fluid through the nozzle. In the embodiment, at least one preformed discharge port 68 is disposed in the wall of the body 52. It is a through hole or slit.

[0123] To achieve the desired drug release profile, the constraining plug 56 and the preformed release Any suitable number and location of exit ports 68 may be used. For example, as shown in FIG. Thus, the device 50 has a single captive plug 56 positioned adjacent both openings. As such, they are shown herein as openings spaced 180 degrees apart from one another within the tubular device body 52. As shown in FIG. 5B, the pair of openings may include two preformed ports 68. The portions 68 and corresponding restraining plugs 56 are provided at or near the respective distal ends of the device. For example, as shown in FIG. 6B, a single A preformed port 68 may be located adjacent each of the captive plugs 56. As shown in FIG. 6B, a preformed port 68 and corresponding restraining plug 56 are provided to may be provided at or near the distal end of each of the

[0124] In some embodiments, the drug delivery device is a No. WO 2014 / 145638 and U.S. Patent Application Publication No. 2016 / 013664, both of which are incorporated herein by reference. In some embodiments, the transmission system may be a transmission system such as that described in US Pat. The drug delivery device comprises a closed wall bounded by a first wall structure and a hydrophilic second wall structure. a drug reservoir lumen and a formulation containing trospium contained within the drug reservoir lumen. a first wall structure that is permeable or impermeable to water; and The first wall structure is impermeable to the drug and the second wall structure is permeable to trospium.

[0125] In some embodiments, the device housing comprises a first wall structure. a drug reservoir of the device made of a material and a second material that functions as a second wall structure. The barrier has a wall that bounds and defines the barrier, and therefore drug release is essentially solely via the second material. In one embodiment, the device does not include an opening and drug release occurs through a second wall structure. As used herein, the terms "impermeable to a drug" and "Water-impermeable" means that the wall structure is substantially impermeable to drugs or water. Thus, drug or water is released essentially through the wall structure over the therapeutic release period. For use in the bladder, the device is flexible (i.e., It is desirable for the device to be flexible and soft to the touch. This is to avoid discomfort and discomfort to the patient. Therefore, the durometer of the first and second materials of the structure is The data is a design consideration, and the proportion of high durometer material provides a good fit within the bladder. While doing so, one may be limited in constructing a device housing of a given size. For example, Tecophilic™ thermoplastic polyurethane (Lubrizol Corp.) can have a Shore hardness of over 70A, such as 80A to 65D, while silicone The tube may have a Shore hardness of 50A to 70A. Therefore, the tube has good water swelling, hydrophilicity, and drug permeability. Rather than fabricating the entire device out of a second material with a different conductivity type, these two different polymer materials are It may be advantageous to utilize a combination of ingredients.

[0126] The arrangement of the first and second wall structures can take a variety of forms. The first wall structure is a cylindrical tube, and the second wall structure is disposed at at least one end of the cylindrical tube. or the first wall structure and the second wall structure are adjacent to each other and together form a cylindrical tube. That is, drug release occurs through a drug permeable structure that defines a portion of the occlusive device housing. The drug permeable wall structure allows the desired drug release from the device to be controlled by drug diffusion through the drug composition. The catheter may be positioned, sized, and have material properties to provide a controlled rate of drug diffusion. In some embodiments, the drug permeable wall extends beyond the lumen of the tube at or near the end of the tube. a disk optionally sandwiched and stabilized between an inner washer and an outer washer; In some embodiments, the drug permeable wall may comprise a portion of the sidewall of the tubular housing. , or part of an end plug located at the end of the tubular housing.

[0127] The length and width of the wall portion formed of the water permeable material are defined by the device housing. The permeability may be selected to provide a desired rate of water flow into the selected reservoir. The width of the aqueous wall portion is defined by the arc angle that defines the wall when viewed in a cross section perpendicular to the luminal axis. The water permeable area of ​​the device housing may be quantified as a selected area of ​​osmotic water absorption, Therefore, to provide speed, the device is preferably made of a suitable biocompatible elastomer. Advantageously, the co-extrusion may be controlled to maintain a suitable overall size and elasticity of the material. By forming the device housing by the extrusion process, the structural changes of the water permeable region are The polymers can be produced in conventional coextrusion devices by selecting the processing parameters. thereby beneficially providing the ability to cost-effectively manufacture multiple structural device configurations. In some embodiments, the length of the water permeable region extends along only a portion of the length of the device. Thus, in such an embodiment, a larger arc angle of the permeable region may be used. while maintaining the drug release rate at a desirable level for an extended period of time. Such an intravesical device housing can be used, for example, as described in U.S. Pat. No. 2016 / 0310 It is described in issue 715.

[0128] In some embodiments, the wall may have a varying thickness around the circumference of the wall, e.g. The drug-permeable portion may have a thickness less than the thickness of the drug-impermeable portion. The thin drug-permeable wall structures are positioned at various positions relative to the adjacent thicker drug-impermeable wall structures. In some embodiments, the drug release may be located within a portion of the occlusive device housing. The drug diffusion is controlled by drug diffusion through a drug-permeable component that defines a drug-permeable wall structure. are positioned and dimensioned to provide a desired rate of controlled drug diffusion from the device. and may have material properties.

[0129] In some embodiments, the drug delivery devices are adjacent to each other and define a drug reservoir lumen. a first wall structure and a second wall structure that together form a tube that defines a drug reservoir lumen; and a drug; and (i) a second wall structure, or a first wall structure and a second wall structure. (ii) a first wall structure is impermeable to a drug; and and the second wall structure is permeable to the drug, such that the drug penetrates the second wall structure. (iii) the second wall structure is releasable in vivo by diffusion through the second wall structure; The structure includes less than 90 percent of the cross-sectional area of ​​the tube in a cross section perpendicular to the longitudinal axis of the tube; (iv) The first wall structure comprises a first polyurethane composition.

[0130] In some embodiments, the device extends between a first closed end and a second closed end. An elongated elastic housing having a drug reservoir lumen and a drug contained within the drug reservoir lumen. (i) the housing is formed entirely of a first material that is impermeable to the drug; and a first annular segment formed of at least a portion of a second material that is permeable to the drug. The second annular segment is formed by diffusion through the second material in the second annular segment. a second annular segment configured to release the agent in vivo by (ii) the first annular segment is integral with a first end of the second annular segment; The first end is formed and connected.

[0131] In some embodiments, the walls defining the drug reservoir lumen may have varying thicknesses. A housing having walls of different thicknesses can vary the flexibility, compressibility, or both of the housing. The different wall thicknesses can also aid in anchoring the solid drug unit within the drug reservoir lumen. This is possible.

[0132] In some embodiments, the intravesical device body or housing is configured to retain the drug during the assembly process. Openings that require sealing after the drug reservoir is filled with the drug filler (e.g., opposing ends of an annular tube) Monolithic housings and modular housing units Any of these defined openings or ends of the housing may be used where blocking of the opening is desired. If necessary, the device may be sealed. This sealing may be achieved by a sealing substance or structure. The insulating structure may be made of metals such as stainless steel, polymers such as silicone, ceramics, or The device is made of a biocompatible material such as sapphire or adhesive, or a combination of both. The sealing material or structure may be biodegradable or biodegradable. In one embodiment, A medical grade silicone adhesive or other adhesive fills the opening in a fluid or effective form. and then hardens within the housing opening to seal the opening. The housing includes one or more predetermined openings for releasing the agent from the device. These drug release openings are sealed and are not defined openings. The housing does not include a predetermined drug release opening.

[0133] In some embodiments, the device has a predetermined drug release opening (i.e., an orifice Drug release from a device without a designated drug release opening. Release can be driven by diffusion or osmotic pressure. Examples of ejection systems are described in WO 2014 / 14406, which is incorporated herein by reference. No. 6 (TB130) and U.S. Patent Application Publication No. 2014 / 0276636 (TB134). It is described in.

[0134] In some embodiments, the drug delivery device is US Patent Application Publication No. 2016 / 0199544, US Patent No. 8,679,094, and Including an infiltration system such as that described in U.S. Patent Publication No. 2016 / 0008271 .

[0135] In some embodiments, the drug delivery device is Penetration as described in US Patent Publication No. 2016 / 0279399 (TB 137) In some embodiments using such a system, trospium is loaded in liquid form into the device housing prior to insertion of the device into the individual's bladder. That's fine.

[0136] In some embodiments, the device includes a housing defining a reservoir and a a first unit contained in the first unit, the first unit including a drug; a second unit housed in the reservoir at a different location from the first unit, The two units function to facilitate in vivo release of trospium from the housing. and a second unit comprising a reservoir. a housing defining a reservoir; and a first unit contained within the reservoir, The unit includes a first unit containing a drug and a reservoir at a location different from the first unit. a second unit contained therein, the second unit being capable of measuring the amount of trospium in urine in the bladder; and a second unit that includes a functional agent that promotes stabilization (e.g., an anti-protease agent). In some embodiments, the first unit comprises at least one drug (e.g., a genomic DNA). one or more solid tablets or powders containing trospium, such as mucitabine, The pack contains one or more solid tablets or powders (e.g., containing an osmotic agent such as urea). In some embodiments, the housing is configured to hold all of the solid tablets of the first and second units in alignment. The catheter is in the form of an elongated elastomeric tube having a lumen (i.e., a reservoir) that is housed within the catheter. The diameter of the solid tablet may be substantially the same as the diameter of the lumen.

[0137] If osmotic release is the desired drug release mode, the functional agent in the second unit acts to mediate the osmotic release of the drug. For example, the osmotic agent may be a stimulant that solubilizes and / or enhances the release of the stimulant. The drug may have a higher solubility than the drug, to facilitate subsequent drug release. Other drugs that have low solubility or that are typically delivered only via diffusion can be delivered from drug delivery-based devices. The device advantageously enables delivery of a sufficient amount of the functional agent and / or drug to be solubilized. The system may undergo an induction period during which the osmotic pressure gradient is established.

[0138] The device then exhibits a zero order release rate for an extended period of time, followed by a decay period. The desired delivery rate can be determined by adjusting various parameters of the device. These parameters can be achieved by controlling / selecting the meter, such as water permeability, The surface area and thickness of the wall, the water permeability of the material used to form the wall, the shape of the openings, These include the size, number, and arrangement of the drug and functional agent, as well as the dissolution profile of the drug and functional agent. Not limited to.

[0139] The devices described herein also provide for delivery of vasopressin by diffusion alone or in combination with osmotic release. The device may also be configured to release the drug in a housing. The device may be configured to allow passage through one or more openings in or on a portion of the housing.

[0140] Alternatively, or in combination with the water-permeable wall portion, the housing may be adapted to prevent fluid from entering the in vivo The reservoir may include at least one opening configured to allow entry into the reservoir. The housing may also include one or more tubings configured to allow passage of the solubilized drug. The opening or passage hole may include

[0141] In some embodiments of the osmotic system, the device housing comprises a first The present invention relates to a method for manufacturing a hose comprising the steps of: forming a hose comprising: a housing; and a second elastomeric material that is water impermeable, the second elastomeric material being formed by a housing having a housing and a housing that is water impermeable. The encapsulation layer is selected to be impermeable to the agent contained within the encapsulation layer.

[0142] 7A-7C show an example of an intravesical device useful in the methods described herein. The device 100 includes a drug reservoir portion 102 and a retaining frame portion 104. In FIG. 7A, device 100 is shown in a relatively expanded form suitable for retention within an individual's bladder. In FIG. 7C, the device 100 is inserted into the urethra and passed through the urethra to the patient. A placement device 200, such as a cystoscope or other catheter, for insertion into a subject's bladder. It is shown in a relatively small profile for placement through the working channel 202. Following deployment (release of the device), the device 100 retains the drug delivery device within the bladder. In an exemplary embodiment, the drug delivery device may assume a relatively expanded shape to accommodate the drug delivery. The drug reservoir and retaining frame portions 102, 104 of 100 are aligned longitudinally. They are integrally formed or otherwise connected to one another along their length.

[0143] The drug delivery device 100 defines a drug reservoir lumen 108 and a retention frame lumen 110. The drug reservoir lumen 108 includes a resilient or flexible device body 106 that holds the drug reservoir. To form the server portion 102, a drug in the form of a plurality of solid drug units 112 (e.g. For example, trospium is contained in the adjacent drug unit 112. The gaps 116 or gaps formed between the drug units 112 allow the drug units 112 to move relative to each other. Thus, the device 100 can be used even when loaded with a drug in solid form. The support frame lumen 110 is formed by the support frame portion 104. The support frame 114 is configured to receive the support frame 114 for supporting the support frame 114.

[0144] As shown in cross-section in FIG. 7B, the device body 106 defines a drug reservoir lumen 108. The support frame includes a tube or wall 122 that defines the support frame lumen 110 and a tube or wall 124 that defines the support frame lumen 110. The tubes 122, 124 and lumens 108, 110 may be substantially cylindrical, with the drug reservoir lumens 108 has a relatively larger diameter than the retaining frame lumen 110, but other configurations may be For example, placement considerations such as the amount of drug to be delivered, the diameter of the holding frame, and the inner diameter of the placement tool. The device body 106 may be formed, for example, by molding or extrusion. Although the tubes 122, 124 may be integrally formed together, separate construction and assembly of the tubes 122, 124 is possible. The wall 124 defining the retaining frame lumen 110 is substantially parallel to the wall 124 defining the drug reservoir lumen 108. 22, such that the retention frame lumen 110 is As shown, the lumen 108 has the same length as the drug reservoir lumen 108, but in other embodiments, one wall is longer than the other. Furthermore, the two walls 122, 124 are the same as the walls 122, 124 of the device in the illustrated embodiment. It is attached along its entire length, although intermittent attachment can also be used.

[0145] As shown in FIG. 7A, the drug reservoir lumen 108 contains multiple drug units 112. For example, about 10 to about 20 drug units 112, such as about 20 to about 80 drug units 112, are loaded in a serial arrangement. The device may be loaded with 100 drug units 112. The drug units may be, for example, tablets, beads, or the like. Essentially, depending on the size of the reservoir and drug unit, Any number of drug units may be used. The drug reservoir lumen 108 is The lumen 108 is provided at each end with open ends 130 and 132, which are shown as relatively circular openings. At least one of the openings is adapted to accommodate a drug reservoir during device loading and assembly. The lumen 108 provides access for a drug unit 112 that is disposed within the lumen 108 .

[0146] The end plug 120 blocks the openings 130 and 132 after the drug unit 112 is loaded. The end plugs 120 may be cylindrical and may be secured by frictional engagement and / or adhesive or other means. The end plugs may be secured within the drug reservoir lumen 108 by fastening means such as 120 provides a passageway for releasing the drug from the drug reservoir lumen 108, as shown. In some alternative embodiments, the end plug includes an opening 118 for providing In some other alternative embodiments, only one of the end plugs includes an opening. In some of these embodiments, the vessel wall 122 does not include a mouth and releases the agent. The device includes a defined opening for receiving the fluid.

[0147] The retaining frame lumen 110 is (thermally) shaped into an overlapping coil shape as shown in FIG. 7A. A retaining frame 114, which may be a resilient wire such as a Nitinol wire, is loaded onto the The retention frame 114 allows the device 100 to be introduced into the body in a relatively small profile. and allowing the device 100 to return to a relatively expanded shape once inside the body. in response to anticipated forces, such as detrusor contraction and fluid forces associated with urination. The device has an elastic limit and modulus that prevents it from assuming a relatively small profile within the body. That's fine.

[0148] e. Erosion-based systems In some embodiments that may be used with tablets containing low solubility drugs, the drug is The present invention provides a method for the preparation of a tablet-shaped composition comprising the steps of: exposing the composition to the outside of the tablet; and fixing the composition to the device. As described in ,816, the release of drug from the device is controlled by erosion / dissolution. In some embodiments, the device includes a modular housing. A modular housing typically comprises at least two separate housings. Each unit is formed of at least one solid drug unit. The material from which the housing unit is formed is at least one material capable of housing the solid drug unit. Each of the drug reservoir lumens defines a drug reservoir lumen. The drug reservoir lumen includes one or more defined openings. For example, the drug reservoir lumen may have at least one drug reservoir lumen contained therein. and two opposing openings exposing corresponding, opposing end faces of the solid pharmaceutical unit. In certain embodiments, at least two separate houses within the modular housing may be used. The housing units are connected, directly or indirectly, by a holding frame. In an embodiment, the modular housing unit is placed on a holding frame to form a "breaker." The device may form a "threat" design. The number of housing units may depend on the holding frame to which they are connected. can be limited only by the size of

[0149] In some embodiments, one or more of the separate housing units includes a shared holding frame. In certain embodiments, each housing unit includes a retaining frame lumen through which the frame extends. The retention frame lumen and the drug reservoir lumen of the knit are arranged parallel to each other. In an embodiment, the retaining frame lumen and the drug reservoir lumen of each housing unit are mutually In a further embodiment, the retaining frame lumen and the The drug reservoir lumen may be angled at angles other than 0° (parallel) and 90° (perpendicular), e.g., 5°, 10° , 30°, 45°, 60°, or 85°. The described device has the following components: (1) a retaining frame lumen and a drug reservoir lumen; (2) the retaining frame lumen and the drug reservoir lumen are disposed substantially parallel to each other; (3) the retaining frame lumen and the drug reservoir lumen are disposed substantially perpendicular to each other; At least two of the following are arranged at angles other than 0° (parallel) and 90° (perpendicular) It includes two or more housing units.

[0150] f. One-piece silicone drug delivery system In some embodiments, the device is a Elastic polymer drug matrices as described in WO 2015 / 200752 may include:

[0151] g. Devices with multiple emitting portions In some embodiments, the device comprises at least two drug releasing portions, One release portion is disclosed in WO 2014 / 023364, the entirety of which is incorporated herein by reference. As described in US Pat. No. 5,999,113, the release of the drug at a rate different from that of another release portion. The release portions can in particular be configured to accommodate different formulations. By having different configurations, or by using different release mechanisms. Different release rates may be achieved by either or a combination of these. These may be combined to achieve a desired release profile. For example, the device may include, among others: , exhibit different onset or lag times before the onset of initial release, release the drug at different rates or according to different release curves, or the drug loading is substantially reduced release of the drug over different periods of time before the drug is released, or a combination of these The heterogeneous release portion may exhibit a relatively short initial lag time followed by a long-term release period. Overall, the drug delivery device exhibits sustained release at a relatively constant rate over a period of time. The active ingredients may be combined to achieve a desired release profile from the formulation.

[0152] In some embodiments, the device may be smaller in size than a conventional pharmaceutical tablet. The device is filled with a drug in the form of a number of solid drug tablets. To control the release of the drug, the drug itself may contain few or no excipients that control the drug release. Instead, the excipients present in pharmaceutical tablets are primarily or entirely absorbed during the tableting process. or may be present to facilitate solubilization in vivo. While providing high drug loading on a volumetric or weight basis, the device is minimally invasive. The nanoparticles may be small enough for in vivo placement in a convenient manner.

[0153] The drug housing may also be in a liquid or semi-solid form upon implantation or after in vivo solubilization. The wall allows the drug to be released either through the drug housing or along its entire length. The wall may be formed of a drug-permeable material that allows for drug flow through at least a portion of the wall. The wall may be made of a material that is partially semi-permeable to the drug depending on the drug form. may be permeable to the drug in some forms, such as a charged form, but not in uncharged forms (e.g. In other forms (e.g., base form vs. salt form), this may not be the case. The walls may also be used to prevent the drug from entering the drug housing. It contains one or more openings or passages formed completely through it that allow air to exit the housing. That's fine.

[0154] The drug moiety can have any combination of the features or configurations described herein. That is, the opening may be provided, omitted, or replaced by a through hole, or an additional opening may be provided. The housing may be reinforced with an aperture or through hole, and may have an open or closed cell structure. and the one or more degradable timing structures or release regulating structures may have a porous wall having The connector may be associated with a housing, a housing, or any combination thereof.

[0155] The drug tablets may be arranged in any configuration other than a straight line arrangement depending on the configuration of the drug housing. The drug tablet may be inserted into any part of the drug housing other than the entire drug housing as described. Any portion of the drug housing that is not filled with a drug tablet may be filled with To achieve this, a filler material such as silicone adhesive may be used, or air may be used to fill the device. The composition of the drug tablet may be the same or may be different from that of the device. The drug may also be administered in other liquid, semi-solid, or solid forms (e.g., granules), etc. It may be in a form other than a tablet.

[0156] In some embodiments, the drug delivery device comprises at least one drug delivery device associated with a single retention portion. The compound also includes two separate or distinct drug moieties, each of which is associated with a carrier moiety. The drug portion may be a separate drug housing, or the drug portion may be a single drug housing associated with the holding portion. It may be a separate area within the housing.

[0157] Each drug portion comprises a portion of a wall of the drug housing and a wall separating the drug portion from a second drug portion. The partition structure may be defined by at least one partition structure having a shape in particular of a cylinder, a sphere or a It may be a plug that is inserted into a housing such as a disk, and may be determined by its size or by its connection. The partition structure is also part of the housing and is fixed in place using a cast adhesive. or the like, directly therein.

[0158] A device having at least two separate portions can dispense at least one drug from a corresponding number of drug reservoirs. The two separate portions may be suitable for controlled release of at least two drug loadings. The two drug fills may have the same or different configurations as those described in the specification. may be the same or may differ in content, such as active ingredient content or excipient content, among others; in a form, such as a salt or base form; in a state, such as a liquid, semi-solid, or solid state; or These combinations may differ from each other in terms of content. The portions may be delivered at the same rate or at different rates via the same or different delivery mechanisms. The two drug loads are released at the same time or at different times, or a combination of both. That's fine.

[0159] For example, some drug moieties are configured to release their drug load relatively quickly after implantation. and another drug portion may be configured to experience a loading period before the start of release; or a combination thereof. An example of a rapid release drug portion is a silicone having a relatively thin wall. The drug portion acts as a relatively fast-acting osmotic pump, such as a tube, A drug portion that is loaded with a drug in a rapid release form, such as a specially formulated solid form, and is relatively fast acting The drug moiety may be associated with a degradable timing structure, or a combination thereof. Thus, the device may release drug during an initial acute phase and during a maintenance phase.

[0160] As another example, certain drug portions may be filled at a relatively faster rate than other drug portions. For example, some drug moieties may be configured to release a drug relatively quickly after implantation. The drug may contain a drug fill having low water solubility for a rapidly initiated diffusional release, and may be combined with another drug The portion may contain a drug load that is highly water soluble for osmotic release after a loading period. For example, a drug moiety may be administered for rapid release via an aperture having a rapidly degrading timing membrane. The drug portion may contain a drug fill in a liquid state for in vivo solubility. The solid tablet may contain an additional pharmaceutical fill for delayed release after formulation. One drug portion may have a relatively solid wall, while another drug portion may increase the release rate by diffusion. a number of openings or holes formed through its walls, or a wall through which water or The may have closed cell porous walls which may increase the release rate due to increased permeation of the drug.

[0161] The release portions may be combined to achieve a desired release profile. For example: The devices may be, in particular, configured to exhibit different onset or lag times before the onset of the initial release. Releasing drugs at different rates or according to different release curves after initiation or drug loading The amount of the drug released may vary over different time periods before being substantially depleted, or a combination thereof. The heterogeneous release portions may exhibit a relatively short initial lag time. After that, the drug was released at a relatively constant rate over a long period of time. may be combined to achieve a desired release profile from the drug delivery device. .

[0162] By combining multiple separate drug moieties within a single device, the device The desired release profile of the spium may be exhibited. The release profile from the device may be: The overall release profile may be the sum of the separate portions. For example, the first portion may be The first part exhibits a minimal lag time before release begins, and the second part has a short lead time due to the development of an osmotic gradient. The third portion exhibits a longer onset period due to the degradable structure dissolving or degrading. Once release begins from any one portion, the release rate continues for an extended period of time. The three separate parts are examples and may be relatively zero order, followed by a decay period. Any number or combination of separate portions may be used to achieve a release profile. Please note that.

[0163] The different drug portions can simply be separate regions within a single tubular housing, thus eliminating the need for separate The device can advantageously be relatively simple to construct and deploy, and furthermore the different drug moieties can be Different release profiles due to different drug loadings, orifice placements, and degradable timing structures The drug portion may be, for example, made of different materials, thicknesses, or walls of a porous cell structure. In other embodiments, the housing may vary along its length or may contain separate agents. A housing may be used. Thus, controlled release may be achieved in a variety of ways. do.

[0164] II. Gel In another embodiment, the coating material is applied to the bladder wall within the bladder (e.g., to the urinary tract within the bladder). The coating material may be applied to the bladder (eg, to the bladder ... Promotes adhesion to the bladder wall, resulting in controlled, continuous drug release over the treatment period1 and one or more excipient materials. The coating material may be a gel, an ointment, a cream, a paste, Mucoadhesive such as a film, emulsion gel, tablet, polymer, or combination thereof The mucoadhesive formulation polymer may be a hydrogel or a hydrophilic polymer. -, polycarbophil (e.g., Carbopol), chitosan, polyvinylpyrrolidone (PVP), lectin, polyethylene glycol polymer, cellulose, or any of these Suitable celluloses include methylcellulose (MC), Carboxymethyl cellulose (CMC), hydroxypropyl cellulose (HPC), or Examples of suitable coating materials include combinations of these. The coating material may include a permeation enhancer. Non-limiting examples of penetration enhancers include dimethylsulfoxide (DMSO), carboxymethyl sodium cellulose (NaCMC), lipids, surfactants, or combinations thereof The coating material is applied to the bladder so that the coating material engages the bladder wall. may be placed in

[0165] The coating material may be placed in the bladder using a placement device. Any device designed to navigate the natural lumen of a blood vessel to reach an intended implantation site. For placement within the bladder, the placement device may be inserted through the individual's urethra or It may be sized and shaped to pass through a suprapubic cystostomy or suprapubic catheter. The placement instrument may be any known device such as a catheter or cystoscope, or a specially designed device. The placement tool may be a device used to place the coating material in the body. and then removed from the body, with the entire coating material remaining embedded within the body. Once implanted in this way, the coating material retains the drug for an extended period of time. Similar procedures may be used to administer any of the devices or agents described herein. The catheter may be deployed to other parts of the body through other natural lumens. The liquid drug is delivered to the urethra or suprapubic vesicostomy by using a device to deliver the drug. Alternatively, the formulation may be placed in the bladder. EXAMPLES

[0166] Example 1: Intravesical delivery of trospium for the treatment of overactive bladder The purpose of this study was to evaluate the efficacy and safety of a Trospium-Releasing Intravesical System (Trospium-Releasing Intravesical System). To confirm the sustained local delivery of trospium using the TAR-302 (Target Cal System) TAR-302 is a passive, non-resorbable, trospium-releasing intravesical system. Its primary mode of action is the controlled release of trospium into the bladder for a period of time, e.g., 42 days. It is out.

[0167] I. Part A. Ten subjects were enrolled in the study. These subjects had idiopathic idiopathic cerebrovascular disease for which oral medications had failed. The patient had an overactive bladder. TAR-302 was placed into the bladder through an insert on day 0 of the study. The drug was removed on day 42 of the study. TAR-302 was administered intravesically for 1 It slowly releases trospium at a dose of approximately 4-8 mg per day. See Figure 3A. .

[0168] Daily urinary recovery of trospium was assessed on days 3, 7, 21, 35, 42, and 56. The mean total daily recovery of trospium on PK sampling days ranged from 3.03 to 8.31 m The gray dashed line represents approximately 20 mg BID or 60 g / day. mg QDs 1 ( 1 Oral trospiran at the Sanctura (FDA-labeled) dose See Figure 8, which shows the estimated daily trospium recovery following administration of trospium.

[0169] TAR-302 therapy resulted in a benign adverse event profile. No evidence of systemic side effects, congestion, or encrustation was observed. At the end of treatment (i.e., day 42), the mean daily urinary incontinence episodes was 5-fold lower than baseline. The T in oral refractory patients was reduced from 0.42 to 1.28. See Figure 9B. The efficacy of AR-302 was demonstrated by a 2.7 reduction from baseline in mean daily urinary incontinence episodes. This is superior to Botox® which provided a reduction in sagging skin. See Figure 10A. The efficacy of TAR-302 also demonstrated a 1- to 1-fold reduction in mean daily urinary incontinence episodes from baseline. VEScare® (Solife), which resulted in a reduction of 0.4 and 0.8, respectively. Nasin succinate) and Detrol LA (tolterodine tartrate) See Figure 10B. Even more surprisingly, TAR-302 A sustained response was observed following removal of TAR-302. Subjects had a daily urinary loss of 2.44 episodes, 55% lower than their baseline of 5.42 episodes. On average, participants had 10 or more abstinence episodes per day (see Figure 9B).

[0170] As shown in Figures 11 and 12, the urinary burden score and quality of life score were also significantly higher than those of the TAR- After 42 days of treatment with TAR-302, urinary strain symptoms were significantly improved. A 40.3% reduction in core was observed. Six weeks after removal of TAR-302, voiding sensation was significantly reduced. The score was reduced by 19.1 points, a clinically meaningful improvement. At the end of the 42-day treatment period with TAR-302, there was a significant 4-fold improvement in quality of life scores. A 2.2-point increase was observed even at day 84, 6 weeks after removal of TAR-302. A significant 17.9-point improvement in quality of life score was observed.

[0171] a. Evaluation items The primary endpoints of TAR-302, including safety, were reported adverse events (AEs), Events (IPE), Physical Exams (PE), Vital Signs, Laboratory Tests, Schedule Based on the results of cystoscopy, bladder ultrasound, post-void residual (PVR), and concomitant medication use, The study was evaluated throughout the study.

[0172] Secondary endpoints included: 1. The tolerability of TAR-302 will be evaluated, for example, by the efficacy and safety of TAR-302 for the specified period. Patients were tolerated and did not meet any of the subject stopping criteria or other drug- or device configuration-related adverse events. Subjects who did not require removal of TAR-302 prior to the scheduled removal date due to meeting any of the following criteria: The results were assessed across studies based on the proportion of participants with ≥ 18% CI, 0.01 to 0.05. 2. Plasma and urine pharmacokinetic analysis was evaluated from day 0 to day 56. For example, plasma trout Rospium exposure and urinary trospium exposure were examined and analyzed. 3. Reduction in incontinence over baseline was assessed from day 0 to day 84. For example, 1 in the number of daily urinary incontinence episodes (incontinence is defined as an instance of involuntary leakage of urine) Negative changes from baseline in the 14.1% to 18.2% were assessed and analyzed. 4. Reduction in daily voiding episodes was assessed from day 0 to day 56. For example, subjects Methods: Negative changes from baseline in toilet voiding frequency were assessed and analyzed. 5. Increase in voided volume per void was evaluated from day 0 to day 56. For example, The increase above baseline measured over a 24-hour period was assessed and analyzed.

[0173] Other outcomes included quality of life (QoL) assessed from days 0 to 84. For example, evidence of improvement in QoL can be assessed by asking subjects the following questions about the past 4 weeks: The subjects were asked to answer one or a combination of the following questions: a. b. The extent to which subjects were bothered by sudden urges to urinate with little or no warning. c. The extent to which the subject was bothered by occasional small amounts of urine leakage. e. The extent to which the examiner was bothered by nighttime urination. f. The subject's awakening at night due to the need to urinate. g. The extent to which subjects were bothered by the strong urge to urinate. h. How often bladder symptoms caused participants to think ahead and make an "escape" to the bathroom in public places i. How often the subject's bladder symptoms made the subject feel like there was something wrong with them. j. k. How often did the subject's bladder symptoms interfere with their ability to sleep well at night? How often did the subject feel dissatisfied or annoyed about the amount of time he or she spent in the bladder? Symptoms may require the subject to refrain from activities that would take them away from the toilet (e.g., walking, running, hiking, etc.). m. How often the subject's bladder symptoms caused the subject to wake up during sleep. n. The subject's bladder symptoms caused the subject to reduce his / her physical activity (exercise, sports, etc.) Frequency. o. Does the subject's bladder symptoms cause the subject to have problems with his or her partner or spouse? p. The frequency with which the subject's bladder symptoms caused the subject to stop at the bathroom while traveling with others. q. How often did the subject's bladder symptoms cause embarrassment to the individual because they had to How often did the subject's bladder symptoms affect his / her relationships with family and friends? How often did the subject's bladder symptoms cause embarrassment? How often have you had to search for the nearest toilet upon arrival?

[0174] b. Eligibility Criteria Inclusion criteria included the following: 1. Subjects had been suffering from urge incontinence or incontinence for at least 6 months. Patients with overactive bladder (OAB) symptoms (frequency / urgency) with mixed urinary incontinence predominantly urge For example, subjects were required to report 8 or more voids per 24 hours as recorded in a diary, or Patients had at least four incontinent episodes associated with urgency, recorded in a 3-day diary (Subjects had at least one episode occurring per 24 hours or per day) 2. Subject has an inappropriate reaction or response to anticholinergic medications for the treatment of OAB. Has limiting side effects.

[0175] Exclusion criteria included: 1. Subjects were under 18 years of age. 2. OAB was due to a neurological disorder. 3. Severe renal insufficiency present at screening. 4. Severe hypertension of any cause at screening 5. Patients with urinary excretion (urinary volume >4,000 mL / day) 6. Patients with a history of pelvic radiation therapy Have a history of either bladder cancer or bladder pathology that the Centers for Disease Control and Prevention consider ineligible for study inclusion. .Except for those treated with expected curative effect and with negligible risk of metastasis or death. 8. Subjects must have had active malignancies within the last 12 months. 9. Has any bladder or urethral anatomical features that may impede placement, indwelling use, or removal. In the opinion of the investigator, the subject has a history of severe stress urinary incontinence. Subjects must have active bladder stones or a history of bladder stones within 6 months prior to study enrollment. Subjects have a history of recurrent symptomatic urinary tract infections (UTIs) (>4 per year). 12. 13. Subjects have either urinary or gastric retention or uncontrolled narrow-angle glaucoma. 14. Subjects have a post-void residual (PVR) of 300 mL or more. 15. Subjects have known hypersensitivity to any of the following: 16. Patient has known hypersensitivity to device materials including silicone and nitinol. The subjects were willing to take oral trospium. 17. Informed consent Within 30 days prior to signing the ICF, you have discontinued your current medications for the treatment of OAB (i.e. anticholinergics, beta-3 adrenergic agonists, anticonvulsants, antidepressants, or The dose of the hormone was newly added or changed. If these drugs were previously used and discontinued, 18. Must have been suspended for more than 2 weeks prior to screening day. Use of intravesical onabotulinumtoxin within the past 9 months prior to admission. 20. Subjects were required to have used intravesical anticholinergic medication within the past 30 days prior to the treatment visit. Have a history of non-drug based therapy for treatment (i.e. InterStim therapy) Non-invasive neuromodulation (i.e., Percutaneous Tibial Nerv A history of post-traumatic stress stimulation (PTNS) for at least 8 weeks prior to study day 0 21. Pregnant women (verified by urine test at screening) ) or women who are breastfeeding or of childbearing potential and are not using an acceptable method of contraception 22. The subject has a medical condition that may result in non-compliance with the study protocol. 23 Subjects must not have participated in any other drug, device, or behavioral study within 60 days prior to the screening visit. 24. The subject is currently undergoing treatment with any condition that, in the opinion of the investigator, would contraindicate participation. Any severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological, History or presence of any chronic or psychiatric illness or disease. 25. Screening A history of any of the following within the last 3 months prior to the visit: Pelvic or lumbar pain unrelated to bladder cancer Major illness / surgery, including surgery or procedures (requiring hospitalization); most outpatient procedures are excluded not be used; renal or ureteral stone disease or instrumentation; childbirth.

[0176] II. Part B. This open-label Phase 1b study is evaluating the efficacy and safety of cyclosporine in patients with idiopathic overactive bladder (IOB) who are refractory or intolerant to oral therapy ( Safety, tolerability, and preliminary efficacy of TAR-302 in patients with iOAB Study subjects had at least four incontinence episodes over a three-day period at study enrollment. Subjects were required to have a single dose of TAR-302 with a bladder residence time of 42 days. TAR-302 was administered once per day using an inserted catheter and removed via a cystoscope. Pharmacokinetic (PK) analysis of blood and urine was performed. Response to TAR-302 was assessed using a 3-day urinary incontinence diary, and quality of life was assessed using the OAB-q short form ( The OAB-q SF was used to evaluate the condition.

[0177] result Eleven subjects successfully completed the study. Baseline characteristics are shown in Table 1. TAR-302 was well tolerated throughout the study. All of the E symptoms were mild, including hematuria (n=4), bladder discomfort (n=2), and bladder pain (n=2). AEs observed typical of antimuscarinic exposure included a single incident of transient dry mouth on day 36. There was only one reported case of pulmonary embolism, which resolved spontaneously. Two subjects reported potential complications from the insertion procedure. I experienced a UTI that may be related to

[0178] PK analysis showed that trospium levels averaged 3.27 μg / mL across the study, with The predicted urinary levels achieved with trospium (0.5–1 μg / mL) were far superior to those achieved with (Sanctura FDA Packag, accessed March 2019) (See Insert e.) These bladder concentrations are consistent with negligible systemic exposure (average : 0.22 ng / mL).

[0179] [Table 1]

[0180] Subjects experienced a decrease from 5.57 events at baseline to 1.4 events at Day 42 (p<0.01). Eleven patients experienced a 75% reduction in their average daily urge urinary incontinence (UI) episodes. Three of the subjects were able to completely inhibit bowel movements by day 42. Both symptom bother and health-related quality of life, as measured by the AB-q SF, were significantly affected. Patients experienced clinically and statistically significant improvements in the symptom distress subscale. The score decreased by 41 points (74 at baseline, 33 at day 42, p <0.01), and the mean score on the HRQOL subscale increased by 45 points ( 32 at baseline and 77 at day 42, p<0.001).

[0181] Surprisingly, subjects did not experience any further progression during this period after removal of TAR-302 on day 42. They appeared to experience lasting symptom benefits despite the lack of any therapeutic intervention. UI episodes remained significantly lower than baseline (2.67 U at day 84). I episodes / day, -52%, p<0.05). Further measures of UI improvement are shown in Table 2. Additionally, clinical (but not statistical) improvements on both OABq-SF subscales were also 84%. Symptom bothersomeness decreased by 19 points (74 points from baseline). 55 at day 84), and HRQOL increased by 18 points (vs. baseline 50 at day 32 vs. day 84, minimal clinically meaningful change = 10 points).

[0182] [Table 2]

[0183] TAR-302 is intended to treat patients with urge urinary incontinence that is not adequately controlled with oral therapy. demonstrated safety, tolerability, and preliminary efficacy in managing symptoms in patients with .

[0184] Example 2 In this study, TAR-302 was administered to subjects with overactive bladder via an insert on Day 0 of the study. The device was inserted into the bladder of each subject, and the device was removed on the 56th day of the study. Immediately afterwards, a different device was used to insert TAR-302. The subjects will be removed on day 112. receive appropriate treatment.

[0185] I. Evaluation items The primary outcome measures were reported adverse events (AEs), investigational drug events (IPEs), and physical examinations ( PE), vital signs, clinical laboratory tests, scheduled cystoscopy, bladder ultrasound Based on bladder postvoid residual (PVR), and concomitant medication use, The safety of TAR-302 was evaluated in

[0186] Secondary endpoints included: 1. The tolerability of TAR-302 will be evaluated, for example, by the efficacy and safety of TAR-302 for the specified period. Patients were tolerated and did not meet any of the subject stopping criteria or other drug- or device configuration-related adverse events. Subjects who did not require removal of TAR-302 prior to the scheduled removal date due to meeting any of the following criteria: The results were assessed across studies based on the proportion of participants with ≥ 18% CI, 0.01 to 0.05. 2. Plasma and urine pharmacokinetic analysis was evaluated from day 0 to day 112. For example, plasma Trospium exposure and urinary trospium exposure will be tested and analyzed. 3. Reduction in incontinence over baseline was assessed over the duration of study participation. For example: , number of daily urinary incontinence episodes (incontinence is defined as any instance of involuntary leakage of urine) Negative changes from baseline in 4. Reduction in daily voiding episodes was assessed from day 0 to day 112. For example, subjects The negative change from baseline in toilet voiding frequency will be assessed and analyzed. 5. The increase in voided volume per void was evaluated from day 0 to day 112. The increase over baseline measured over a 24-hour period is assessed and analyzed.

[0187] Other outcomes included quality of life (QoL), assessed from days 0 to 112. For example, evidence of improvement in QoL could be provided by asking subjects to The subject is assessed by answering one or a combination of the following questions: b. The extent to which subjects were bothered by the sudden urge to urinate with little or no warning. c. The extent to which the subject was bothered by occasional small amounts of urine leakage. e. f. The extent to which the subject was bothered by nighttime urination. g. The degree to which subjects suffered from urinary incontinence due to a strong urge to urinate. h. The frequency of bladder symptoms in subjects led them to think ahead and make "escapes" to public restrooms i. How often the subject's bladder symptoms made the subject feel like there was something wrong with him / her. j. How often did the subject's bladder symptoms interfere with a good night's sleep? How often did the subject feel dissatisfied or annoyed about the amount of time he or she spent in the bathroom? Bladder symptoms prompted subjects to refrain from activities that would take them away from the toilet (e.g., walking, running, hiking, etc.). m. How often the subject's bladder symptoms caused the subject to wake up during sleep n. The subject's bladder symptoms cause the subject to reduce his / her physical activity (exercise, sports, etc.) o. How often did the subject's bladder symptoms cause the subject to have problems with his or her partner or spouse? p. How often did the subject's bladder symptoms cause the subject to stop at the bathroom while traveling with others? How often did the subject's bladder symptoms cause embarrassment? How often did the subject's bladder symptoms affect his / her relationships with family and friends? How often did the subject's bladder symptoms cause embarrassment at a new place? How often have you had to search for the nearest toilet as soon as you arrive?

[0188] Example 3: TAR-1 in subjects with idiopathic overactive bladder (iOAB) and urinary incontinence A prospective, multicenter, open-label study of trospium delivered intravesically by 302-5018 Experiment - Part 1. TAR-302-5018 contains 850 mg of trospium chloride and is It was shown to release an average of 10 mg / day over a 42-day retention period in an ro study. This average daily release rate is estimated for humans assuming a urine production rate of 1500 mL / day. This is estimated to produce a urinary concentration of 7 μg / mL.

[0189] I. Purpose The objective of the study is to evaluate the safety of one dosing cycle of TAR-302-5018 for up to 42 days. To evaluate efficacy and tolerability of TAR-302-5018 and to evaluate urinary and To evaluate the pharmacokinetics (PK) of trospium exposure in plasma and to assess the effect of urinary incontinence, urinary symptoms (excretion Trospium for urinary frequency episodes and volume, and quality of life (QoL) symptoms and determining the effect of continuous intravesical release of

[0190] II. Methodology Patients with iOAB accompanied by urge urinary incontinence that is refractory or intolerant to oral anticholinergic therapy Subjects were screened for inclusion in the study. On day 0, the TARIS inserter TAR-302-5018 was then delivered transurethrally to eligible subjects. TAR-302-5018 was removed by either flexible or rigid cystoscopy. For safety and efficacy evaluation, subjects were recruited approximately 42 h after removal of TAR-302-5018. The follow-up was completed on day 84 (±7 days). In addition, follow-up was performed on days 0, 3 (±1 day), and 7 Days 1 (± 1 day), 21 (± 1 day), 35 (± 2 days), 42, and 56 (± PK evaluation was performed at the visit on the 2nd day of the study. The 27th (± 1 day), 38th (± 1 day), and 49th (± 1 day) days Subjects were contacted by telephone between clinic visits.

[0191] Approximately 10 subjects were planned to be enrolled in this part of the study. 12 subjects The 12 subjects were enrolled and insertion of TAR-302-5018 was performed. Eleven subjects were enrolled in the intent-to-treat (ITT) and safety populations. Patients completed the study and were enrolled in the Per-Protocol (PP) population.

[0192] III. Diagnosis and Main Criteria for Inclusion To be eligible to participate in this study, subjects must meet the following inclusion criteria at the time of enrollment: All of the following conditions had to be met: 1. Urge incontinence or urgency component for at least 6 months Symptoms of overactive bladder (OAB) (frequency / urgency) with mixed urinary incontinence predominantly Subjects were required to have 8 or more voids per 24 hours as recorded in a diary and / or a 3-day diary have at least four incontinent episodes associated with urgency, recorded in At least one episode must have occurred every 24 hours in any one day. Inadequate response or limiting side effects from anticholinergic drugs for the treatment of OAB.

[0193] Subjects were eligible for inclusion in the study if they met any one of the following exclusion criteria: 1. Age < 18 years. 2. OAB caused by a neurological condition. 3. Presence of severe renal insufficiency (glomerular filtration rate <30 mL / min) at screening. 4 Presence of severe polyuria due to any cause at screening (urine volume ≥ 4,000 mL / day) 5. History of pelvic radiation. 6. Bladder cancer that the investigator considers ineligible for study inclusion. 7. History of either cancer or bladder pathology. 8. Metastasis or death treated with the hope of cure. Active malignant tumors within 12 months, except those with negligible risk of relapse. 8.TAR-302 Any bladder or urethral anatomy that may prevent safe placement, indwelling use, or removal of the 5018 9. Subjects with severe stress urinary insufficiency in the opinion of the investigator. 10. Active bladder stones or a history of bladder stones within 6 months prior to study enrollment. 11. Subjects with a history of recurrent symptomatic urinary tract infections (UTIs) (>4 per year) 12. Subjects with either urinary or gastric retention or uncontrolled narrow-angle glaucoma. 14. Post-void residual (PVR) of 0 mL or more. 15. Subjects with known hypersensitivity to the vehicle. 16. Subjects with known hypersensitivity to chair materials. 17. Subjects who have completed the study within 3 days before signing the Informed Consent Form (ICF) Current medications for the treatment of OAB (i.e., anticholinergics, beta-3 adrenergic drugs) within 0 days New dosages of drugs (renergic agonists, anticonvulsants, antidepressants, or hormones) Stable doses must be continued until the final study visit. If these drugs have been used previously and discontinued, for more than 2 weeks prior to Day 0, 18. Intravesical bladder cancer within the past 9 months prior to the screening visit. 19. Use of onabotulinumtoxin. 20. Urinary tract infection within the past 30 days prior to the screening visit. Intravesical anticholinergics were used. 20. Non-pharmacological therapies for the treatment of OAB (i.e., Inte History of Percutaneous Tibial Nerve Streptomy. Non-invasive neuromodulation such as post-natal neuroimaging (PTNS) was performed at least on day 0 of the study. 21. Pregnant women (if urine test was not performed at screening) (verified by the National Institute of Infectious Diseases) or are breastfeeding or may become pregnant and are using an acceptable method of contraception 22. Subject has a medical condition that may result in non-compliance with the study protocol. 23. Subject refused to provide written informed consent. 24. Subjects will be required to complete questionnaires and / or diaries and / or all Unable or unwilling to attend study visits required by the protocol 25. Use of another drug, device, or behavioral test within 60 days prior to the screening visit. 26. Any severe condition that, in the opinion of the investigator, contraindicates participation in the study. cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological, and 27. History or presence of psychiatric disorders or illnesses within 3 months prior to the screening visit. History of any of the following: Major illness / surgery, including pelvic or lower back surgery or procedures unrelated to bladder cancer (requiring hospitalization); most outpatient procedures were not excluded; renal or ureteral stone disease or 28. Difficulty in providing a blood sample. 29. Clinical trial investigator Any other unspecified reason that, in the judgment of the attending investigator or TARIS, made the subject unsuitable for enrollment. .

[0194] IV. Endpoints Primary Safety Endpoint Safety of TAR-302-5018 upon insertion, 42 days of continuous exposure, and removal. Safety was assessed using treatment-emergent adverse events (TEAEs). , clinical laboratory tests, vital signs, physical examination, bladder ultrasound, investigational drug events (IPEs), Bladder PVR evaluation, cystoscopy, and concomitant medications were assessed.

[0195] b. Secondary Safety Endpoints Tolerability of TAR-302-5018 upon insertion, 42 days of continuous exposure, and removal. Tolerability should be evaluated based on protocol-specific subject stopping criteria or adverse events related to other drug or device configurations. Requires removal prior to the scheduled date due to the satisfaction of any of the following events (AEs): Plasma and urine PK analysis (day 0, day 3 (±1 day), day 7 ( ±1 day), 21st day (±1 day), 35th day (±2 days), 42nd day, and 56th day (±2 days) Plasma and urine samples were used to measure the maximum concentration (Cmax), maximum The test date (Tmax), the concentration at elimination on the 42nd day (Ctau), and the average concentration from day 0 to day 42 The average concentration (Cave 42) and the average concentration from days 0 to 56 (Cave 56) were determined.

[0196] c. Preliminary Efficacy Endpoints Defined as a negative change from baseline in the number of daily episodes of urinary incontinence The reduction in urinary incontinence was observed at days 0 (baseline), 42, and 84 ( Incidents of involuntary urinary leakage as recorded in the subject's bladder diary during the 3 days prior to the visit (±7 days) The baseline, 3 days (± 1 day), 7 days (± 1 day), and 2 Before visits on days 1 (± 1 day), 35 (± 2 days), 42, and 56 (± 2 days) Baseline number of times subjects voided into a toilet as recorded in a subject diary during a 4-hour period Reduction in daily voiding episodes defined as a negative change from baseline. Day 0 (baseline), day 3 (± 1 day), day 7 (± 1 day), day 21 (± 1 day), Measured over 24 hours prior to visit on days 35 (± 2 days), 42, and 56 (± 2 days). Voiding per void above baseline, determined and recorded by the subject in a diary Increase in quantity.

[0197] d. Additional Efficacy Endpoints OAB-q short completed at study sites on days 0, 42, and 84 (± 7 days) Evidence of improvement in QoL as assessed by the form.

[0198] V. Statistical methods Analysis population ITT population: TAR-302-5018 on day 0, whether or not it was successful All enrolled subjects in whom an insertion procedure was attempted were included.

[0199] PP group: TAR-302-5018 insertion procedure was successful, with no significant protocol deviations This includes all subjects who retained TAR-302-5018 for the entire 42-day treatment period. Major protocol deviations were defined prior to database lock.

[0200] Safety Population: All enrolled patients who underwent successful TAR-302-5018 insertion procedures In this study, the ITT and safety populations were the same, and the results of the ITT population were is presented.

[0201] b. Determining sample size The sample size was not based on statistical considerations.

[0202] c.Effectiveness Number of urinary incontinence episodes during the 3 days prior to the designated visit; number of voids during the 3 days prior to the designated visit; and total voided volume for each 24-hour collection period, along with the change from baseline, were described by time point. Summary of subject responses (>50% reduction from baseline in urinary incontinence episodes) reduction in urinary incontinence episodes by more than 75% from baseline, and The OAB-q score was 100% reduction from baseline at days 42 and 84. The scores on the symptom form were converted as defined in the clinical trial report. Severity scores and converted health-related QoL scores were summarised descriptively by time point.

[0203] d. Pharmacokinetics Plasma and urinary trospium were summarized descriptively by time. Plasma and urinary Cmax, Tmax, Ctau, Cave42, and Cave56 were summarized descriptively.

[0204] e. Safety Medical Dictionary for Regulatory Activities AEs were coded using the MedDRA Index version 20.0. TEAEs were summarized by dDRA system organ class and preferred terminology. Further, the severity, relationship (to drug configuration, device configuration, or TARIS inserter), and expectancy Between days (0 to 42, 42 to 49 [± 1 day], and 0 to 49 [± 1 day] Serious adverse events (SAEs) were also summarized narratively. Vital signs and clinical laboratory assessments were summarized descriptively, along with changes. Physical examination dates were listed. The number of subjects who tolerated TAR-302-5018 was presented. IPE results were summarized narratively. Bladder PVR results were summarized narratively. Bladder ultrasound en Results of bladder and urinary tract cystoscopic evaluation are listed by subject. Previous and concomitant medications were recorded in the World Health Organization Drug Dictionary Encyclopedia of They were coded using ced (B3 December 2017 version) and summarised descriptively.

[0205] VI. Summary and Conclusions Efficacy Results The mean number of incontinent episodes was approximately 75%, and approximately 52% in the 3 days prior to day 84 (± 7 days).

[0206] At day 42, approximately 82% of subjects in the PP population had a baseline urinary incontinence episode had a greater than 50% reduction from baseline, with 64% of subjects having a greater than 75% reduction from baseline; 27% of subjects had a 100% reduction from baseline. Approximately 46% of these subjects reported a greater than 50% decrease from baseline, and 18% reported a The company reported a decline of more than 75% from baseline.

[0207] In the PP population, the mean number of voiding episodes during a 24-hour period was The mean mean score was 1.4, and the mean mean score was 1.4 on days 3 (± 1 day), 7 (± 1 day), and 21 (± 1 day) ), 35th day (±2 days), 42nd day, and 56th day (±2 days) were approximately 8%, 12%, and 1 Decreases of 2%, 14%, 8%, and 11% were observed.

[0208] In the PP population, mean 24-hour urine volume was 0.01 on days 3 (±1 day), 7 (±1 day), and 21. From baseline on days 35 (± 1 day), 42 (± 2 days), and 56 (± 2 days) However, these findings were observed concomitantly with a decrease in bladder PVR.

[0209] In the PP population, the mean converted symptom severity score was approximately 55% at day 42 and 84 ( ±7 days), indicating a reduction in subject-reported symptom severity.

[0210] In the PP population, the mean converted health-related quality of life (HRQL) scores were significantly higher at day 42 The increase in subject-reported QoL was approximately 143% at day 1 and approximately 58% at day 84 (± 7 days). It showed addition.

[0211] b. Pharmacokinetic results After insertion of the TAR-302-5018 system, urinary trospium concentrations were In 9 of 11 subjects and in all 11 subjects in the PP population on day 7 (± 1 day) The mean concentration on day 7 was 5258 ng / mL.

[0212] The majority of urine concentrations were within the predicted range of 2000–6000 ng / mL, with the target concentration being 4. The mean urinary trospium concentration was maintained until day 2. The mean urinary trospium concentration was 526 The peak was 3822ng / mL on day 35 (±2 days) and 3822ng / mL on day 42 (±2 days). It decreased to 565ng / mL.

[0213] Detectable plasma concentrations were rare. Samples with measurable trospium plasma concentrations The concentrations observed did not follow a consistent time course and did not correlate with measured urinary concentrations, urine volume, or urine Confirmatory analysis using an independent bioanalytical method demonstrated that plasma External contamination of the samples was found in two known samples with detectable trospium concentrations. These two samples were excluded from the overall trospike data. Uric acid concentrations were consistently low (<0.7 ng / mL).

[0214] Overall, the urinary and plasma concentrations in this study were generally consistent with previous nonclinical findings. there was.

[0215] c. Safety Results TAR-302-5018 was well tolerated. Based on the protocol-specific definition of tolerability, Based on this, no subjects were considered to be intolerant to TAR-302-5018. .

[0216] No subjects discontinued treatment prematurely due to either TEAEs or IPEs.1 One subject withdrew consent and discontinued TAR-302-5018 on day 21, but the remaining subjects Eleven subjects continued to use TAR-302-5018 as planned through the Day 42 visit. The patient continued on and completed the study.

[0217] The most common TEAEs during the 42-day treatment period were hematuria (4 of 12 subjects, 33.3 %), UTI (2 of 12 subjects, 16.7%), bladder pain (2 of 12 subjects, 16 .7%), bladder discomfort (2 of 12 subjects, 16.7%), and sinusitis (12 subjects, 16.7%). The majority of AEs were mild.

[0218] One drug-related TEAE was reported: dry mouth. The most frequent device-related TEAE was The most common symptoms were hematuria (4 of 12 subjects, 33.3%), bladder discomfort (2 of 12 subjects, 16. 7%), and bladder pain (2 of 12 subjects, 16.7%). Two subjects At least one TARIS inserter-related TEAE was reported. Events included nausea, vomiting, Chills, fever, UTI, elevated white blood cell count, lactic acidosis, dysuria, hematuria, and peri-renal Peripheral hydrocele was reported in all subjects (8.3%) and in one subject in one case. Urethral pain was reported (8.3%).

[0219] The mean changes from baseline in laboratory parameters were generally small. The finding of occult bleeding (at any level) after in-line was greatest on day 21 (± 1 day) (4 1.7%), 27.3% on day 42, and 9.1% on day 84 (± 7 days). of subjects had hematuria reported as a TEAE, with one of these reports being , in subjects with an SAE of UTI.

[0220] The mean changes from baseline in blood pressure, heart rate, respiratory rate, and temperature were small and clinically The results were not meaningful in any meaningful way. There was no one there.

[0221] Mean bladder PVR was measured at 7 days (± 1 day), 21 days (± 1 day) and 1 week after screening. On day 35 (± 2 days), there was a decrease of approximately 21%, 42%, and 29%, respectively.

[0222] A bladder co-examination revealed no urothelial bleeding, no evidence of bladder stones, and no bladder diverticulum. No evidence of cystitis was observed. Bladder ultrasound evaluation on day 21 (± 1 day) or at the time of removal showed no evidence of urinary tract infection. No cases of crustosis were observed.

[0223] One IPE involving injury to TAR-302-5018 was reported, and the investigator The subjects suspected that the discomfort occurred during gripping to remove the system. Neither study participant nor any other TEAEs were reported.

[0224] d. Conclusion Overall, TAR-302-5018 has an acceptable safety profile. was found to be well tolerated over the 42-day indwelling period, with urinary Concentrations were consistently produced with limited systemic exposure. In this patient population, There was a reduction in subject-reported symptom severity scores and improved QoL, as well as a reduction in urge incontinence episodes. A significant reduction in sword count was observed. The maximum effect was observed on day 42, but the baseline Sustained and meaningful improvement from in- 6 weeks after removal of TAR-302-5018 This was also evident in the final examination evaluation.

[0225] Example 4: TAR-1 in subjects with idiopathic overactive bladder (iOAB) and urinary incontinence A prospective, multicenter, open-label study of trospium delivered intravesically by 302-5018 Experiment - Part 2. Trospium-releasing intravesical system (TAR-302-5018) was inserted on study day 0. The drug is administered into the bladder via a catheter and removed on day 84 of the study. The catheter gradually releases trospium during the indwelling period.

[0226] I. Evaluation items As shown in Figure 15A, the safety of TAR-302-5018 is 0, 14, 56, 84, Safety was assessed at days 112 and 132. , physical exam (PE), vital signs, clinical laboratory tests, scheduled cystoscopy Based on bladder ultrasound, postvoid residual (PVR), and concomitant medication use, was evaluated throughout the body.

[0227] The tolerability of TAR-302-5018 was evaluated. The patient was tolerant to 18 placements and met the subject discontinuation criteria or other drug- or device configuration-related adverse events. Requires removal of TAR-302-5018 prior to the scheduled date by satisfying any of the following: Percentage of subjects without

[0228] Plasma and urine pharmacokinetic analyses [time frame: Day 0 to Day 112] were performed. , including analyses of plasma trospium exposure and urinary trospium exposure.

[0229] Reduction in urinary incontinence over baseline [time frame: Day 0 to Day 112] was assessed Changes from baseline in the number of daily urinary incontinence episodes were assessed. It is defined as an instance of involuntary leakage of urine.

[0230] Reduction in daily voiding episodes was evaluated [time frame: Day 0 to Day 112]. The change from baseline in the number of times participants voided to the toilet was assessed.

[0231] The increase in voided volume per void was evaluated [time frame: day 0 to day 112]. Changes from baseline as measured over two 24-hour periods were assessed.

[0232] Other outcome measures included quality of life measures assessed by the OAB-q Short Form. These include the core and distress scores.

[0233] II. Inclusion Criteria Idiopathic with urge incontinence or mixed incontinence with a predominantly urge component for at least 6 months Patients with symptoms of overactive bladder (iOAB) (frequency / urgency) were enrolled. Subjects were required to have 8 or more voids per 24 hours as recorded in a diary or to have 3 days of diary Have at least four documented incontinent episodes associated with urgency (or At least one episode occurs every 24 hours.

[0234] The subject had an inadequate response or inhibition to previous oral medications for the treatment of OAB. Patients were included even if they were experiencing limiting side effects, at the investigator's discretion.

[0235] III. Exclusion Criteria Patients who met any of the following conditions were excluded: 1. Age <18 years. 2. Neurological bladder status. 3. Subjects with diabetes mellitus (both type 1 and type 2) Optimal HbA1c level of less than 7.5% via urine dipstick at screening Demonstrated good glycemic control and no severe diabetes defined as 3+ glucose 4. Presence of severe polyuria of any cause at screening 5. The first morning urine sample taken during nighttime (afternoon) sleep. at study screening, defined as >30% of the total 24-hour urine volume, including voids prior to study screening 6. History of pelvic irradiation. 7. Patients who the investigator considers unsuitable for inclusion in the study. History of either bladder cancer or bladder pathology that is considered to be irrelevant. 9. Investigator currently using intermittent catheterization (IC) to Any bladder or urinary obstruction that, in the opinion of the 10. Subjects with urethral anatomical features (e.g., urethral strictures). Subjects with a history of bladder stones within 6 months prior to enrollment. 12. Uncontrollable bleeding, bleeding diathesis, or underlying coagulation disorder within 30 days of Day 0 13. In the opinion of the investigator, the subject has a history of severe stress urinary incontinence 14.0 Days: Have a history of more than two symptomatic urinary tract infections in the 6 months prior to day 0. 5. Subjects with urinary retention or gastric retention or uncontrolled narrow-angle glaucoma within 90 days from day 0 16. Post-void residual (PVR) of 100 mL or more. 17. Trospium, chemical 18. Subjects with known hypersensitivity to any of the following drugs or excipients: Silicone and Nitto Subjects with known hypersensitivity to device materials containing phenol. 2 weeks prior to Day 19.0 Within a short time, anticholinergics or beta-3 agonists were used to treat urge incontinence. 0. History of intravesical onabotulinumtoxin use within the past 9 months prior to the screening visit 21. Administered intravesical anticholinergic drugs within the past 14 days prior to the screening visit. 2. Treatment-based neuromodulation therapies for the treatment of OAB (e.g., InterStim Therapy) , Percutaneous Tibial Nerve Stimulation[P 23. History of pregnancy (verified by serum testing at screening). 24. Subjects may, in the discretion of the investigator, 25. Have a medical condition that may result in non-compliance with the art book. or are unable or unable to attend all protocol-mandated study visits. 26. Subjects who have received another drug, drug combination, or 27. Participated in any severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal, or gynecological disorder. Gynecologic, endocrine, immunological, dermatological, neurological, or psychiatric disorder or disease or the presence or absence of any medical condition that, in the opinion of the Investigator or TARIS, may prevent the enrollment of a subject. Any other unspecified reason for ineligibility. 28. Any of the following within 3 months prior to the screening visit: History of any of the following: i. Major illness / surgery (requiring hospitalization), including pelvic or lower back surgery or procedures; Most outpatient procedures are not excluded; ii. Prostate cancer within 6 months prior to childbirth. 29.0 days 30. History of severe pelvic organ prolapse (grade 3 or higher). 31. Difficulty providing a blood sample. 32. Within 12 months prior to screening 33. Known history of drug or alcohol abuse within the past 24 hours. Any other unspecified reason that, at the discretion of the study participant, made the subject unsuitable for enrollment.

[0236] As shown in FIG. 15A, daily urinary incontinence events were counted on days 0, 14, 56, 84, and 112. As shown in Figure 15B, before treatment, patients had an average of 5.23 urinary incontinence episodes per day. On day 14, the average daily urinary incontinence episodes increased by 2 At day 56, the average daily urinary incontinence episodes was reduced by 44% from baseline to 0.9. At day 84, the mean daily urinary incontinence episodes were reduced from 0.0 to 3.0, a 43% reduction. The mean mean bladder thrombosis rate was reduced from baseline to 2.3, a 56% reduction. Long-term local delivery of pium has been shown to be effective in treating overactive bladder.

Claims

1. A method for training the bladder of an individual with overactive bladder comprising administering an effective amount of trospium to a patient. topically to the bladder of said individual for at least about 24 hours.

2. A method for prolonging symptomatic relief in an individual with overactive bladder comprising administering an effective amount of trospium to said individual. and administering locally to the bladder for at least about 24 hours, said individual receiving trospium wherein relief of symptoms is experienced for at least about 24 hours after administration is completed.

3. A method for improving the quality of life of an individual with overactive bladder comprising administering an effective amount of trospium to and administering the medicament to the bladder for at least about 24 hours, wherein the quality of life of the individual is improved by administering the medicament to the bladder for at least about 24 hours. The method is improved by treatment with lospium.

4. The individual with overactive bladder may continue to have bladder problems for at least about 7 days after trospium administration is completed.

4. The method according to claim 1, wherein the patient experiences at least about 50% relief of baseline symptoms. The method according to claim 5.

5. Trospium is administered continuously locally to the bladder for at least about 42 days. The method according to any one of items 1 to 4.

6. The method comprises administering an effective amount of trospium to the bladder every three months or as needed (prn). The method of any one of claims 1 to 4, further comprising administering the

7. Continuously administering an effective amount of trospium locally to the bladder of an individual for at least about 42 days.

46. ​​A method for treating overactive bladder, comprising:

8. Trospium is administered continuously for about 56 days, about 84 days, or about 12 weeks. Item 7. The method according to item 7.

9. 7. The method of claim 6, wherein trospium is administered continuously for at least about 12 weeks.

10. A method for the maintenance treatment of overactive bladder in an individual, comprising administering trospium to a patient for at least about 24 hours. and administering the same continuously and locally to the bladder for a period of time, said individual being treated for pre-existing overactive bladder. The method of treatment you have received.

11. The maintenance therapy comprises administering an effective amount of trospium to the bladder for at least about 24 hours every three months.

11. The method of claim 10, comprising administering locally to the bladder.

12. The maintenance therapy comprises administering an effective amount of trospium as needed (prn) for at least about 24 hours.

11. The method of claim 10, comprising administering locally to the bladder for a period of time.

13. The maintenance therapy comprises administering an effective amount of trospium for at least about 24 hours upon recurrence of symptoms.

11. The method of claim 10, comprising administering locally to the bladder.

14. The maintenance therapy begins when the individual experiences a recurrence of at least 50% of baseline symptoms. and administering an effective amount of trospium locally to said bladder for at least about 24 hours. The method of claim 10, comprising:

15. The prior treatment comprises administering an effective amount of trospium for at least about 24 hours and for at least about 42 days. for at least about 56 days, at least about 84 days, or at least about 12 weeks.

11. The method of claim 10, comprising administering locally to the bladder.

16. The concentration of trospium in the bladder is 0.1 to 100 μg / m during administration of trospium. The method according to any one of claims 1 to 15, wherein L is

17. The concentration of trospium in the individual's plasma is less than 2 ng / mL during administration of trospium. The method according to any one of claims 1 to 16, wherein

18. The method according to any one of claims 1 to 17, wherein the individual has idiopathic overactive bladder. .

19. The individual has or has previously had multiple sclerosis, Alzheimer's disease, Parkinson's disease. The method according to any one of claims 1 to 18, wherein the patient has suffered a stroke.

20. 18. The method of claim 1, wherein the individual has had a history of failure in prior treatments for overactive bladder.

13. The method according to claim 1.

21. The individual has no prior treatment for overactive bladder. The method according to claim 5.

22. The individual has failed oral therapy or is ineligible for oral therapy.

19. The method according to any one of claims 18 to 18.

23. The method according to any one of claims 1 to 22, wherein the individual has urinary incontinence or urge incontinence. How to.

24. The method according to claim 1 to 5, which results in neural remodeling or remodeling of neural networks.

24. The method according to any one of claims 23.

25. 25. The method according to claim 1, wherein symptomatic relief of urgency, frequency or urinary incontinence is achieved. The method described.

26. The method according to any one of claims 1 to 25, wherein the quality of life score of the individual is improved. .

27. The method according to any one of claims 1 to 26, wherein the individual's urinary strain score is reduced. Law.

28. The method of any one of claims 1 to 27, wherein the method reduces the abnormal urge to urinate.

29. Trospium is administered to the bladder by using an intravesical device. Item 29. The method according to any one of items 1 to 28.